{
  "name" : "dacemirror.sci-hub.se_journal-article_397f24e71375db7fef4c33cc917f8a25_li2018.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Emerging Nanotechnologies for Liquid Biopsy: The Detection of Circulating Tumor Cells and Extracellular Vesicles",
    "authors" : [ "Wenzhe Li", "Huayi Wang", "Zijian Zhao", "Houqian Gao", "Changliang Liu", "Ling Zhu", "Chen Wang", "Yanlian Yang" ],
    "emails" : [ "zhul@nanoctr.cn;", "wangch@nanoctr.cn;", "yangyl@nanoctr.cn" ],
    "sections" : [ {
      "heading" : null,
      "text" : "REVIEW\n1805344 (1 of 25) © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.advmat.de\nEmerging Nanotechnologies for Liquid Biopsy: The Detection of Circulating Tumor Cells and Extracellular Vesicles\nWenzhe Li, Huayi Wang, Zijian Zhao, Houqian Gao, Changliang Liu, Ling Zhu,* Chen Wang,* and Yanlian Yang*\nW. Li, H. Wang, Dr. Z. Zhao, H. Gao, C. Liu, Dr. L. Zhu, Prof. C. Wang, Prof. Y. Yang CAS Key Laboratory of Standardization and Measurement for Nanotechnology CAS Key Laboratory of Biological Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology Beijing 100190, China E-mail: zhul@nanoctr.cn; wangch@nanoctr.cn; yangyl@nanoctr.cn\nThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adma.201805344.\nDOI: 10.1002/adma.201805344"
    }, {
      "heading" : "1. Introduction",
      "text" : "Biopsy has been clinically used to diagnose diseases for over ten centuries and has become the routine assessment and golden standard for the diagnosis of many diseases such as cancer.[1] In the recent decades, with the introduction and development of new technologies such as immunohistochemistry (IHC)[2] and fluorescent in situ hybridization (FISH), biopsy could provide not only the histological information but also the molecular\nLiquid biopsy enables noninvasive and dynamic analysis of molecular or cellular biomarkers, and therefore holds great potential for the diagnosis, prognosis, monitoring of disease progress and treatment efficacy, understanding of disease mechanisms, and identification of therapeutic targets for drug development. In this review, the recent progress in nanomaterials, nanostructures, nanodevices, and nanosensors for liquid biopsy is summarized, with a focus on the detection and molecular characterization of circulating tumor cells (CTCs) and extracellular vesicles (EVs). The developments and advances of nanomaterials and nanostructures in enhancing the sensitivity, specificity, and purity for the detection of CTCs and EVs are discussed. Sensing techniques for signal transduction and amplification as well as visualization strategies are also discussed. New technologies for the reversible release of the isolated CTCs and EVs and for single-CTC/EV analysis are summarized. Emerging microfluidic platforms for the integral on-chip isolation, detection, and molecular analysis are also included. The opportunities, challenges, and prospects of these innovative materials and technologies, especially with regard to their feasibility in clinical applications, are discussed. The applications of nanotechnologybased liquid biopsy will bring new insight into the clinical practice in monitoring and treatment of tumor and other significant diseases.\nNanotechnologies\ninformation (e.g., the expression of target genes and proteins, and genetic mutations) of cancer, which greatly contributed to the treatment management of cancer.[3,4] However, despite the great progress made in biopsy techniques and targeted therapies, the morbidity, metastasis rate, and mortality of cancer are still high. One reason is that the traditional biopsy assessments are performed on the tumor tissue obtained from surgery or fine-needle aspiration (FNA). These assessments are usually performed after the detection of mass lesion by medical imaging that is normally evident long after the pathological process and onset of cancer.[5] Patients at this stage often miss the chance for early treatment. The invasive procedure to obtain tissue specimens limits the application of tissue-based biopsy for the routine disease screening. Noninvasive biopsy, in this regard, provides a good opportunity for early diagnosis and early treatment. Second, targeted therapies are normally according to the assessments on the primary tumor tissues, and the prescriptions\noften last until the recurrence and metastasis of tumor due to the difficulties and risk to obtain multiple and serial tissue biopsies, especially for patients who have undergone tumor resection and are anatomically challenging to reconduct tumor tissues. However, the assessments on the primary tumor tissues may not represent the real-time status of the molecular markers as their expression may change during tumor progression and cancer treatment due to tumor evolution and heterogeneity, which largely affects the efficacy of the targeted treatments.[6,7] Moreover, single-biopsy, either a portion of specimen obtained from surgery or a single-needle aspiration, may not represent the overall genomic landscape of a tumor and may bring evaluation bias due to intertumoral and intratumoral heterogeneity.[8] An alternate to the tissue-based biopsy that can provide multiple and serial specimens for the integral and dynamic monitoring of cancer progress and treatment response is highly desired for personalized management of cancer.\nTo address these challenges, a new concept termed liquid biopsy that is based on the analysis of biomarkers (e.g., circulating tumor cells (CTCs), cell-free nucleic acids (cfNAs), and extracellular vesicles (EVs)) in the body fluids, normally the peripheral blood, has been proposed.[1,9] In 1869, Ashworth\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (2 of 25)\nreported the presence of CTCs in the blood of a metastatic breast cancer patient.[10] These cells are suggested to escape from the primary site, enter the bloodstream, migrate with circulation, and finally reach a secondary site and form a tumor colony (Figure 1).[11,12] CTCs are demonstrated to be associated with metastasis and tumor initiation, and exhibit great diagnostic and prognostic value.[12,13] In 1948, Mandel and Metais described the presence of cell-free nucleic acid in human blood.[14] Increasing attention has been paid to cfDNA as a liquid biopsy since 1990s when the alterations on cfDNA were found in cancer patients.[15,16] EVs were first discovered by Trams et al. in 1981.[17] The functionality of EVs was not highlighted until late 1990s when the secretion of EVs by B lymphocytes and dendritic cells was reported showing the importance of EVs in antigen presentation and immune response.[18,19] These endosome-derived extracellular vesicles (30–150 nm in diameter) are released by almost all the mammalian cells and are abundant in various body fluids including the blood.[20,21] They play critical roles in intercellular communications by transferring proteins, lipids, and nucleic acids (e.g., messenger RNA (mRNA) and microRNA (miRNA)) from their originating cells to the recipient cells, participate in the physiological and pathological processes, stimulate tumor progression and metastasis (Figure 1), and have therefore been taken as an emerging liquid biopsy.[2,22,23] Numerous technologies and methodologies have been developed to detect and analyze these liquid biopsies, and have shown the value of liquid biopsies in the early diagnosis, dynamic monitoring, and prognosis evaluation of cancer.[24–27]\nNanotechnology, characterized by utilizing the materials, structures, and devices whose sizes and functions are in the range of 1–1000 nm in at least one dimension,[28,29] has shown its overwhelming advantages in liquid biopsy. First, biological detection requires efficient enrichment and high sensitivity as many biomarkers have a low concentration in the body fluids. For example, CTCs are usually present from one to several cells per milliliter of blood.[30–32] Nanostructures have large surface area relative to volume, and can therefore enable increased interaction between the materials and the analytes to enhance the capture of the rare cells in the blood. Second, the small dimension of nanostructures benefits for the capture and enrichment of nanoscaled biomarkers such as EVs (30–100 nm), and helps to amplify the localized signals from the nanoscaled EVs especially when the nanostructures are densely organized. Moreover, the detection of CTCs and EVs is challenging due to the complicated components (e.g., normal blood cells, cell debris, etc.) of the body fluids that normally hamper the capture of CTCs and EVs and shield the signals from these biomarkers. Nanostructures and nanodevices provide a platform for the precise detection of CTCs and EVs as a result of their small sizes.[28] Third, biomarkers may undergo minor changes at the preclinical stage before the onset of the diseases or during disease progression and treatment. Nanotechnologies, taking advantages of their small dimensions, have enhanced electrical, magnetic, optical, mechanical, or thermal characteristics to provide readable signals for early diagnosis and dynamic monitoring of diseases. Fourth, cancers are heterogenous. Subpopulations of CTCs have been observed and have been demonstrated to be associated with cancer progression and drug resistance.[33,34] Enumeration alone fails to offer the whole information of CTCs and EVs. Nanotechnologies provide integrated and versatile platforms for the lab-on-chip detection and downstream molecular analysis of CTCs and EVs, and hold great potential for the application in the clinic.[35] Last but not\nWenzhe Li received her B.S. degree in chemistry from Shandong University in 2014. She then joined Professor Yang’s group in the same year at the National Center for Nanoscience and Technology (NCNST). She is now a Ph.D. candidate at the NCNST, jointly trained with Peking University. Her research is mainly focused on the\nnanotechnology-based method for the detection of tumorderived exosomes.\nLing Zhu is currently an associate professor at the National Center for Nanoscience and Technology (NCNST). She received her B.S. degree in medicine at Chongqing Medical University in China in 2005 and her Ph.D. degree in molecular biology and biomedicine at University of the Basque Country in Spain in 2013.\nShe joined NCNST in 2013. Her research interests focus on the design and synthesis of peptides and peptoids for molecular recognition, and biological detection based on peptide and peptoid nanostructures.\nYanlian Yang is a Professor of the National Center for Nanoscience and Technology (NCNST). She received B.S. and M.S. degrees in chemistry from Shandong University and obtained her Ph.D. degree in physical chemistry from Peking University in 2002. Then, she worked as a postdoctoral researcher at Peking University for two\nyears before she joined NCNST. She was a visiting scholar at Massachusetts Institute of Technology from 2007 to 2008. Her research interests include liquid biopsy based on peptide nanostructures, molecular mechanism, and modulation of peptide assembly structures associated with diseases, and the development of new nanocharacterization methods based on scanning probe microscopy.\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (3 of 25)\nleast, the good biocompatibility of nanomaterials not only enables efficient capture of CTCs and EVs, but also keeps the biomarkers intact for cell culture and further molecular analysis.\nHere, we review the development and advances of nanotechnologies in biological detection, with a focus on the detection and analysis of CTCs and EVs. The detection and analysis of cfDNA involve the development of sequencing techniques and are out of the scope of this review. We summarize the recent progress in nanomaterials, nanostructures, nanosensors, and nanodevices for the isolation and detection of CTCs and EVs. Their advances and challenges in the sensitivity, specificity, signal transduction and amplification, visualization, and reversible release are discussed. Novel techniques for single CTC/EV analysis and integrated microfluidic platform for the on-chip detection and analysis of CTCs and EVs are also reviewed. We also discuss the standardization of these nanotechnologies for achieving the reproducible and trustable results in liquid biopsy."
    }, {
      "heading" : "2. Advances and Challenges of NanotechnologyBased Liquid Biopsy",
      "text" : "Most liquid biopsy strategies include the enrichment of targets from the body fluids such as the peripheral blood and the subsequent characterization and analysis of the isolated targets. Current isolation and enrichment of CTCs and EVs are mainly based on two approaches: the separation of CTCs and EVs based on their characteristic physical properties (e.g., size,[36,37] deformability,[38,39] and adhesion[40]) and the immunoaffinitybased enrichment, usually in virtue of molecular probes such as antibodies,[41,42] peptides,[43] and aptamers.[44,45]\nThe isolated CTCs and EVs are subsequently detected by fluorescent visualization or electrochemical and plasmonic sensing, etc., and their molecular biomarkers (e.g., proteins, DNA, and RNA) are analyzed by immunostaining, reverse transcription-polymerase chain reaction (RT-PCR), and sequencing, etc. (Figure 2).[46–51] Various nanomaterials, nanostructures, and molecular probes have been developed for the enrichment and analysis of CTCs and EVs, and have been successfully applied in the clinic, showing the potential of nanotechnologybased liquid biopsy in early diagnosis, dynamic monitoring, treatment response evaluation, point-of-care testing (POCT), and prognosis prediction (Figure 3).[52–55] Challenges in liquid biopsy such as sensitivity, specificity, reversible release and visualization, and the advances and breakthroughs of nanotechnology in these issues are discussed in this section."
    }, {
      "heading" : "2.1. Nanobiological Interface for Improved Specificity and Sensitivity",
      "text" : "Specificity and sensitivity are two main concerns for biological detection, especially for the detection of limited targets in the complicated biological samples, e.g. the identification of CTCs (one to several CTCs mL−1) from billions of normal blood cells in the blood and the identification of tumor-derived exosomes from the abundant extracellular vesicles released by various normal cells.[9,56] Moreover, sufficient sensitivity to capture the minor changes of the liquid biopsies is essential for the early diagnosis and monitoring of cancer progression and treatment response. Various probes (antibodies,[41,57] peptides,[58,59] aptamers,[60,61] etc.) have been applied to improve the specificity for biological\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (4 of 25)\ndetection. Meanwhile, numerous nanomaterials such as nanoparticles and grapheme oxide, as well as nanostructures such as nanowires and nanofibers have been developed to enhance the capture capacity of CTCs and EVs taking advantages of their nanoscaled size that are comparable to the ones of biomolecules and their large surface-to-volume area that enables increased biological–material interfaces for improved binding and the amplified signals in the localized environment (Tables 1 and 2).[62,63] These probes, in combination with the novel nanomaterials and nanostructures, have greatly improved the detection efficiency of CTCs and EVs, and have achieved a lot of clinical applications."
    }, {
      "heading" : "2.1.1. Probes for Enhancing the Detection Capacity",
      "text" : "Immunoaffinity-based capture is one of the most common strategies for the isolation of CTCs and EVs. Probes specific to the marker membrane proteins on CTCs and EVs are widely used to capture CTCs and EVs. These markers include cancerspecific proteins such as epithelial cell adhesion molecule (EpCAM) that is highly expressed in various epithelial carcinomas,[56,64–68] epidermal growth factor receptor (EGFR) that is highly expressed in lung cancer, glioma, gastric cancer, etc., epidermal growth factor receptor 2 (HER2) that is an important diagnostic and prognostic marker for breast cancer, prostatespecific membrane antigen (PSMA) and prostate-specific antigen (PSA) that are highly expressed in prostate cancer, and EV-specific proteins such as CD63, CD81, etc.[9,12,69–72] Antibodies are the most common probes and have been widely used to coat various nanomaterials and nanostructures.[73–75] Peptides are used as a type of surrogates for antibodies since the molecular recognition between the antigens and the antibodies is manly involved in short peptides at the contacting interfaces. Peptides have small size, high stability, and are easy to be synthesized, making them a promising probe for biological detection.[76,77] Many high affinity peptides have been designed and screened for the detection of CTCs and EVs, and have achieved high capture efficiency comparable to antibodies.[77–79] For example, Bai et al. reported a de novo designed EpCAM recognition peptide that had better stability and higher binding affinity to EpCAM compared to the antibody. They used magnetic nanoparticles (MNPs) functionalized with this EpCAMtargeting peptide to capture CTCs and reached a capture rate of above 90%.[58] Several years later, the same group reported a de novo designed peptide with high affinity to HER2, and used the peptide-functionalized MNPs to capture HER2-positive CTCs in breast cancer, achieving a capture efficiency of 68.56–79.26%.[43] Aptamers are single-stranded DNA or RNA oligonucleotides that fold into unique 3D conformations. Owning to their capability to bind target molecules with high affinity and specificity, aptamers have also been used to isolate CTCs and EVs.[60,61,80] The expression of biomarkers may vary in different CTCs or\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (7 of 25)\nMirkin’s group developed a NanoFlare system in which a spherical gold nanoparticle was functionalized with a densely packed monolayer of single-strand DNA (ssDNA) targeting intracellular mRNA, and the ssDNA was hybridized to a Cy5-labeled short DNA complement reporter flare whose fluorescence was quenched due to its proximity.[84,85] Upon binding to the target mRNA, the reporter flare was displaced, providing a fluorescent readout. The NanoFlare system was combined with flow cytometry analysis and was applied for the detection and molecular analysis of live CTCs in breast cancer.[86] Zheng and co-workers developed a lipid nanoprobe (LNP) system in which the lipid bilayer of EVs was decorated with biotin-tagged 1,2-distearoyl-sn-glycero3-phosphethanolamine–poly(ethylene glycol) (DSPE–PEG) for the collection by NeutrAvidin (NA)-coated magnetic submicrometer particles (MMPs), and utilized this system for the detection and the downstream analysis of EGFR and KRAS mutations in the plasma from nonsmall-cell lung cancer patients.[87]"
    }, {
      "heading" : "2.1.2. Nanomaterial-Based Detection and Analysis",
      "text" : "MNPs are one of the earliest and most classical nanomaterials for the detection of CTCs. MNPs have a relatively high surface to volume ratio, resulting in higher binding capacity and capture efficiency. Their fast binding kinetics enables rapid enrichment of the targets. Moreover, they are stable in solution without aggregation or precipitation.[74,88,89] Due to these advantages, MNPs are widely used as the fundamental materials for the immunoaffinity-based isolation of CTCs. In these immunoaffinity-based CTC isolation strategies, MNPs are functionalized with probes, normally the antibodies specific to the marker membrane proteins (e.g., EpCAM) on CTCs to isolate CTCs from the blood. The most representative example is CellSearch system that is the only system approved by the U.S. Food and Drug Administration (FDA) up to now for evaluating the diagnosis and prognostic effect of metastatic breast and colorectal cancer patients. Using the CellSearch platform, several groups have shown the correlation between CTC enumeration and patients’ clinical outcome.[66,90,91] Strategies have been taken to improve the sensitivity of the MNP-based isolation of CTC. For example, improvements have been made on the probe that is functionalized on the MNPs, as was reported by Bai et al. and Peng et al. who modified the MNPs with de novo designed peptides that had high affinity to the marker membrane proteins on CTCs (e.g., EpCAM and HER2) (Figure 4a).[43,58] The peptide-functionalized MNPs exhibited high capture efficiency for the CTCs in breast, prostate, and liver cancers, reaching a capture rate of above 90% for CTCs or 68% for HER2 positive CTCs, much higher than the one with antibody-functionalized MNPs[43,91] showing the potential of high affinity peptides as probes for improving the detection sensitivity. Slow magnetic response and high loss rate have been the problems for MNPs due to the small size of the nanoparticles. To solve these problems, Wen et al. constructed magnetic nanospheres (MNs) by layer-by-layer (LBL) assembly method that enabled effective control of the size and magnetic response of the nanospheres (Figure 4b).[92] Five layers of hydrophobic nano-γ-Fe2O3 were assembled on the surface of the poly(styrene/acrylamide) copolymer nanospheres (Pst-AAm-COOH) to get rapid magnetic response, and\nan outer layer of silica was introduced to increase the stability and decrease the aggregation of the nanospheres. Using breast cancer cells SK-BR-3 spiked into the healthy human blood as a model system, the MNs functionalized with anti-EpCAM exhibited a capture efficiency of above 94% via a 5 min incubation. The isolated CTCs remained viable at 90.5 ± 1.2%, and could be transferred to culture, reverse transcription-polymerase chain reaction, and immunocytochemistry (ICC) analysis. The relative standard deviation of the isolated CTCs was calculated to be 10.8%, confirming the good reproducibility and reliability of this method. The LBL MNs were successfully used to differentiate patients with colon, liver, lung, or breast cancers to the healthy individuals, showing the potential of this material to analyze clinical samples. The MNPs were also coated with other materials, for example the carbon nanomaterials, to enhance their stability and biocompatibility in order to prevent the magnetic core from oxidation and degradation and to therefore maintain a high magnetism.[14,20] For example, Chen et al. used graphite-coated MNPs microarray to detect CTCs.[93] The stable and biocompatible graphite-coated MNPs were proved to be a good tool for CTC enrichment from the complex systems such as the whole blood. This magnetic nanocrystal-based detection approach may also be extended to other biological detection applications. The MNPs were also coated with the cell membranes to decrease the nonspecific binding of the impurities (e.g., normal blood cells) in the blood and to therefore improve the specificity of the isolation methods and techniques. For example, Xie and coworkers coated the Fe3O4 magnetic nanoclusters (MNCs) with engineered leukocyte membrane (decorated with anti-EpCAM through mild and effective click chemistry)[94,95] for CTC enrichment from the blood.[96] The leukocyte membrane-functionalized MNCs would be repelled when they encounter the leukocytes due to their homology.[97] The nonspecific adsorption of leukocytes was therefore significantly decreased. As a result, 90% of CTCs could be captured from whole blood in 15 min with an undetectable leukocyte background. Liu and co-workers coated the immuno-MNPs with platelet–leukocyte hybrid membranes to enhance the capture efficiency of CTCs taking advantage of the binding affinity of platelets to CTCs and the capability of white blood cells to reduce nonspecific binding.[98] The hybrid membrane-coated immune MNPs exhibited a cell separation efficiency of 66.68% and the cell purity of 96.98% in the breast cancer cell MCF7-spiked blood and showed great ability in identifying breast cancer patients.\nApart from MNPs, other nanomaterials such as graphene/ graphene oxide (GO),[73,99] gold nanoparticles,[100] and silicon nanowires[101] were also used for biological detection. It is well known that the nanostructured materials improve cell attachment by providing increased interface on the nanoscaled topography for the adhesion of cells.[102,103] These nanostructured materials, when functionalized with probes, can therefore serve as desirable scaffolds for biological detection as a result of the increased density of probes on the surfaces.[62,63,102,104] Inspired by this, Wan et al. used 3D nanotextured polydimethylsiloxane (PDMS) substrates functionalized with aptamers specific to EGFR to capture CTCs, achieving a twofold improvement in the sensitivity for CTC capture compared with that of the glass slides or plain PDMS.[104] GO, due to its nanotextured morphology and easy-tobe modified chemical property, have gained a lot of attention in\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (8 of 25)\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (9 of 25)\nthe identification of CTCs and EVs.[73,82,105] Yoon et al. developed a patterned gold surface coated with EpCAM antibody-functionalized GO nanosheets, and used it for the identification of CTCs from the blood from metastatic breast cancer, metastatic pancreatic cancer, and early-stage lung cancer.[105] The GO nanosheets were adsorbed onto the patterned gold surface through electrostatic attraction and were subsequently functionalized with biotinylated EpCAM antibodies through NeutrAvidin and biotin interactions (Figure 4c). This material was able to capture CTCs at low concentrations with high sensitivity (73 ± 32.4% at 3–5 cells mL−1 blood). The nanotextured morphology and roughness of GO provided not only the nanoscaled interfaces but also a 3D trap effect for CTC recognition (Figure 4d).[73,106]\nZhang et al. developed a nanointerfaced microfluidic EV (nanoIMEX) platform based on layer-by-layer coating the surface of the channel and the Y-shaped microposts with antibody-functionalized GO-induced nanostructured polydopamine (PDA) (Figure 4e).[107] This GO/PDA coating 3D nanostructured interface enhances the capacity for EV detection, and allows for the subsequent ultrasensitive enzyme-linked immunosorbent assays (ELISA) of the captured EV, achieving a very low detection limit of 50 µL−1 with a 4-log dynamic range. They demonstrated the clinical application of this method by successfully distinguishing ovarian cancer patients from the healthy donors using unprocessed plasma with the minimal volume (2 µL) for analysis. These results showed the potential of the GO-based materials in liquid biopsy.\nGold nanoparticles have been used to develop biosensors taking advantages of their plasmonic features[47] and their aggregation strategies for biotarget detection.[108] Inci et al. created a nanoplasmonic electrical field–enhanced resonating device (NE2RD) based on gold nanoparticle (10 nm diameter)modified polystyrene surfaces where the inter-nanoparticle distance is reduced by 3D self-assembly. The gold nanoparticle-modified surface was functionalized with antibodies for immunodetection of the biological targets. NE2RD yielded a label-free optical readout by precisely measuring collective oscillations of the self-assembled gold nanoparticles on the surface (Figure 4f).[75] This device was able to detect multiple biotargets (i.e., protein biomarkers, drugs, protein allergens, bacteria, eukaryotic cells, and distinct viruses) from distinct clinical matrices such as saliva, serum, and the whole blood, and could be used as a disposable fluidic chip format for diagnostic applications in the POCT settings. For the detection of IFN-γ, which is a well-known biomarker for tuberculosis, the NE2RD exhibited the detection limit as low as 400 fg mL−1 (P < 0.05), nearly 3 orders of magnitude better than that of ELISA"
    }, {
      "heading" : "2.1.3. Nanostructure-Based Isolation and Enrichment",
      "text" : "Nanostructures have advantages in biological detection due to their nanoscaled size that is similar to the ones of the biological targets and their topographic structure that can enhance\nthe capture efficiency via increasing the biological–material contacting interfaces. Nanoporous structures have been widely used for the isolation of CTCs based on the differences of physical properties between CTCs and other hematologic cells in the blood.[37,109–114] These studies led to the application of nanoporous structures for the isolation of EVs from the other impurities in the body fluids. Demirci co-workers developed EV total isolation chip (ExoTIC) which was consisted of a series of nanoporous filter membranes with different pore sizes (Figure 5a).[115] This nanopore-based filtration system was able to enrich and purity EVs directly from the clinical samples (e.g., culture media, plasma, and urine) in a size range of 30–200 nm, while the other impurities in the samples such as free nucleic acids, proteins, lipids, and other small fragments were flushed out. The ExoTIC system exhibited comparable capture efficiency to the one with ultracentrifugation that was the most commonly used method for EV isolation.[116,117]\nIt is well known that the nanoscaled cellular surface components (e.g., microvilli and filopodia) and extracellular matrix (ECM) play critical roles as scaffolds in cell–cell interactions such as adhesion.[118,119] Inspired by the nanostructure-mediated cell–cell interaction, nanostructured substrates such as nanopillars,[42,120,121] nanofibers,[122,123] and novel DNAbased nanostructures[124] that share similar dimensions, the topography with the cellular surface components, and the ECM scaffolds have been constructed to improve the capture efficiency of CTCs and EVs due to the enhanced local topographical interactions.\nIn the past few years, Tseng and co-workers at University of California, Los Angeles (UCLA), pioneered a unique concept of “NanoVelcro” cell-affinity substrates in which the antibodyfunctionalized silicon nanopillar (SiNP) substrates were used to enhance the capture efficiency of CTCs (Figure 5b).[42,123,125,128,129] In NanoVelcro, the densely packed silicon nanopillars provide enhanced local topographic interactions between the substrates and the nanoscaled components of the cellular surface, and thus results in significantly improved cell-capture affinity compared to the unstructured substrates.[125] Tseng and coworkers also developed an antibody-functionalized electrospun TiO2 nanofiber (TiNF) substrate for the capture of CTCs.[123] Different from the vertically oriented silicon nanopillars previously employed for CTC enrichment,[42,130] TiNFs were horizontally packed, better mimicked the horizontal orientation of nanostructures embedded in the ECM scaffolds, and therefore improve the cell/nanostructures affinity (Figure 5c). Utilizing the anti-EpCAM-coated TiNF substrates, they performed the CTC-capture studies on peripheral blood samples from colorectal and gastric cancer patients. CTCs were captured in two of three cases with counts ranging from 0 to 2 CTCs per 0.5 mL blood sample of colorectal cancer patients, and seven of seven cases with counts ranging from 3 to 19 CTCs per 0.5 mL blood sample of gastric cancer patients, respectively. These results demonstrated the high sensitivity of this platform\nAdv. Mater. 2018, 1805344\nWiley-VCH. e) Scheme of the nanointerfaced microfluidic EV platform (nano-IMEX). The glass/PDMS surface of the channel was coated with antibodyfunctionalized graphene oxide/polydopamine-nanostructured interface for the detection and subsequent sandwich ELISA of EVs. Reproduced with permission.[107] Copyright 2016, Royal Society of Chemistry. f) Representation of the NE2RD platform. Gold nanoparticles are immobilized on the polystyrene surfaces via poly-l-lysine. Several activators and antibody anchors are used to immobilize antibodies onto the surface for immunodetection. Reproduced with permission.[75] Copyright 2015, National Academy of Sciences.\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (10 of 25)\nfor the capture of CTCs. By grafting a poly(acrylamidophenyl boronic acid) (poly AAPBA) brush from aligned silicon nanowire (SiNWs) array, Wang and co-workers designed a pH and glucose dual responsive surface that can reversibly capture and release cancer cells (Figure 5d).[126] At pH 6.8 without glucose, the polymer brush can bind specifically with the overexpressed sialic acid on the surface of the cancer cells. When increasing the glucose concentration to 70 × 10−3 m and simultaneously evaluating the pH to 7.8, the added glucose can replace the sialic acid and form a stable complex with the poly AAPBA, thus releasing the captured cells. In addition, the SiNW array also plays an important role in the process of cell capture and release. They provided a 3D topographical interaction between the nanostructured SiNWs and cell\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (11 of 25)\nprotrusions, thus greatly enhance the responsiveness and accelerate the response rate of cell capture and release.\nIn addition to the inorganic nanomaterial-based (i.e., silicon, TiO2, and PLGA) nanostructures, DNA nanostructures have also attracted intense interest because of their unparalleled self-recognition properties that offer flexibility and convenience for the “bottom-up” construction of precise nanostructures with high controllability and precision.[124] Many recent progresses have been made in the development of 3D DNA architectures and their application in biological detection.[131–134] In particular, the DNA nanotetrahedra (NTH) structures that are self-assembled from four single-stranded sequences have mechanical rigidity and structural stability, and have been successfully applied in the detection of nucleic acids, proteins, small molecules, and cells.[124,135,136] More recently, Wang et al. developed a portable electrochemical aptasensor for the detection of EVs based on aptamer-functionalized NTHs immobilized on the gold surface (Figure 5e).[127] The pyramidal nanostructure of NTN provided a stable scaffold for the ordered immobilization of aptamers and therefore significantly increased the sensitivity of aptamers. The detectable concentration was demonstrated to decrease from 108 to 106 EVs mL−1, and the detectable range was also expanded."
    }, {
      "heading" : "2.2. Signal Transduction and Amplification for the Detection and Visualization of CTCs and EVs",
      "text" : "Large-scale clinical application of liquid biopsy requires signal transduction and visualization techniques for the easy detection and readout of the quantity and the molecular information of the biological targets. Moreover, the signals from rare tumor cells and the nanoscaled EVs are easy to be shielded by the background. To detect subtle changes of the biotargets during disease progress, especially at the early stage of tumor, is even more difficult. Signal amplification, in this regard, is critical for increasing the sensitivity of biological detection. Various nanotechnologies and biosensing systems have been developed to transduce and amplify the signals from the captured CTCs and EVs taking advantages of the optical, mechanical, electrical, and magnetic relaxation properties of the nanomaterials and nanostructures (Table 2).[127,137,138] These techniques not only achieved low limit of detection, but also provided opportunities for the direct imaging and visualization of the captured CTCs and EVs, and therefore hold great potential for the development of POCT technologies.[46]"
    }, {
      "heading" : "2.2.1. Signal Transduction and Amplification",
      "text" : "Common signal transduction and amplification systems include the electrochemical assays, plasmonic sensing systems, surfaceenhanced Raman scattering systems, etc. Electrochemical sensors are a common type of signal transduction and amplification system for the sensitively detection of biological targets through the electrochemical impedance change, redox reaction–induced signal amplification, or electromagnetic signal transduction.[80,112,139–141] Zhou et al. reported an aptamer-functionalized electrochemical biosensor for the quantitative detection of\nEVs.[80] Aptamers specific to CD63 were immobilized onto the gold electrode surfaces and probing strands prelabeled with redox moieties were hybridized onto the aptamers. In the presence of EVs, these beacons released probing strands with redox reporters, causing the decrease of electrochemical signal. This sensing system could detect as few as 1 × 106 EVs mL−1, achieving 100-fold decrease of the detection limit compared to the ones with most of the commercial immunoassays. Jeong et al. developed the integrated magnetic electrochemical EV (iMEX) system for the fast and streamlined analysis of EVs by combining MNP-based isolation and electrochemical sensing.[142] The iMEX platform has eight detection channels. Each channel was equipped with a potentiostat capable of measuring a wide range of current (±7.5 µA). EVs are first captured onto immunomagnetic beads. Secondary antibodies with an oxidizing enzyme (horseradish peroxidase, HRP) are then added, followed by mixing the beads with chromogenic electron mediators (3,3ʹ,5,5ʹ-tetramethylbenzidine, TMB) which generate electrical current when HRP is encountered (Figure 6a). The iMEX was able to detect EVs at a sensitivity of <105 vesicles. The potential clinical utility of iMEX was further demonstrated by profiling EVs collected from ovarian cancer patients showing that the expression levels of EpCAM and CD24 in EVs were much higher in ovarian cancer patients than in the healthy controls, and both metrics showed high correlation.\nPlasmonic biosensing has drawn much attention as they have many advantages such as high stability in harsh environment, label-free and real-time detection capabilities, and rapid response.[143,144] Among the diverse plasmonic devices, surface plasmon resonance (SPR) is most commonly used to detect molecular interactions occurring in proximity to a precious metal (gold/silver) surface based on monitoring reflection changes resulting from molecular binding.[145] Lee and co-workers developed a novel SPR-based assay, named nanoplasmonic EV (nPLEX) sensor, for the label-free and highthroughput analysis of EVs.[146] The system was based on the optical transmission through an array of periodic nanoholes patterned in the gold films[147,148] rather than the total internal reflection[143] as was used in the conventional SPR. Each nanohole had a diameter of 200 nm and a periodicity of 450 nm in a 200 nm thick gold film. Each array was functionalized with affinity ligands specific to different exosomal protein markers. Upon EV capture, the nPLEX sensor changed its local refractive index, and thus displayed spectral shifts or intensity changes proportional to the levels of the targeted protein markers (Figure 6b). Using nPLEX to analyze ascites samples from ovarian cancer patients and noncancerous patients, they found that EVs derived from ovarian cancer cells can be identified by their expression of CD24 and EpCAM, with the accuracy of 93% for EpCAM and 87% for CD24, pairing protein level profiles of EpCAM and CD24 further increased the diagnostic accuracy to 97%. In a more recent work, this technique was used to diagnose pancreatic ductal adenocarcinoma (PDAC), obtaining an overall sensitivity of 86% for detecting PDAC and a specificity of 81% for differentiating PDAC from other pancreatic diseases.[149] Liang et al. described a nanoparticle-enhanced scattering (nPES) assay for the detection of EVs (Figure 6c). Based on the principle that gold nanoparticles (GNPs) with different size and shape scatter light at characteristic wavelengths, EVs\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (12 of 25)\ncaptured by antibody-functionalized surface were labeled with 50 nm gold nanospheres (AuS) with green scattering light and 25 × 60 nm gold nanorods (AuR) with red scattering light. Since the diameter of EVs was <200 nm, the scattering of AuS and AuR that bound to EVs was coupled, resulting in a local plasmon that shifted the spectra of the scattered light to yellow\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (13 of 25)\nand strongly enhanced the intensity of the scattered light.[49] Utilizing the AuS–EV–AuR complex, they achieved rapid and ultrasensitive isolation and quantification of EVs from just 1 µL of plasma, and demonstrated diagnostic value of this platform in pancreatic adenocarcinoma, with the performance superior to the standard clinical biomarker carbohydrate antigen 19-9 (CA 19-9).\nSurface-enhanced Raman scattering (SERS) is also commonly used for the sensitive multiplex biological detection because of its single molecule level sensitivity,[151,152] molecular specificity,[153] and insensitivity to quenching.[154] To obtain reproducible SERS enhancement, metallic nanostructures with precisely controlled shapes and sizes have been developed.[155,156] Wu et al. developed gold-based SERS nanoparticles to directly detect CTCs from the blood without prepurification process.[157] The nanoparticles were modified with the Raman reporter molecule 4-mercaptobenzoic acid (4-MBA) to achieve strong SERS signals, folic acid (FA) to specifically identify CTCs, and stabilized with reductive bovine serum albumin (rBSA) to reduce the nonspecific binding. They compared gold nanoparticles with different shapes and demonstrated that the gold nanostars (AuNSs) exhibited best sensitivity, achieving a detection limit of 1 cell mL−1 blood that was much lower than the currently reported one (5 cells mL−1 blood).\nInspired by the capacity of DNA catalytic reaction in sensitively detecting nucleic acids in vitro,[158,159] Lee and co-workers developed lipid–polymer hybrid nanoparticles (LPHN)-catalyzed hairpin DNA circuit (CHDC) biochip capable of highly sensitive imaging and quantification of target RNAs in EVs.[150] A specific CHDC consisting two hairpin DNAs (H1, H2) and a reporter (a DNA duplex labeled with a fluorophore and quencher) for GPC1 mRNA[149,160] was encapsulated in LPHNs, which were then tethered on a thin glass slide through biotin–avidin interactions (Figure 6d). Cationic LPHNs were able to capture negatively charged EVs by electrostatic interactions. The resulting LPHN–EV fusion led to the mix of CHDC with the target RNA, and the allosteric transformations of CHDC could be catalytically triggered by hybridizing with target RNAs and a reporter, and thus provided fluorescent signal amplification. The ultrahigh sensitivity of the LPHN–CHDC complexes was demonstrated by detecting GPC1 mRNA in pancreatic cancer EVs, revealing that the system was able to detect EVs from pancreatic cancer cell line as low as 105 mL−1 (≈60 EVs µL−1). LPHN–CHDC was demonstrated to be able to distinguish PDAC patients with stage I–IV from healthy donors and patients with BPD."
    }, {
      "heading" : "2.2.2. Visualization",
      "text" : "A variety of nanomaterials (e.g., Fe3O4 nanoparticles,[161,162] gold,[163,164] quantum dots,[165] and graphene oxide nanosheets[166]) and nanotechnologies have been involved in the imaging and visualization of biological targets such as the nucleic acids, proteins, cells, and EVs. Colorimetric detection is perhaps the simplest and most convenient way as the readout only requires naked eyes. Based on the finding that single stranded DNA can enhance the intrinsic peroxidaselike activity of the nanozyme,[167] Wang et al. designed a novel hybrid nanozyme by coupling the peroxidase-like graphitic\ncarbon nitride nanosheets (g-C3N4 nanosheets) with ssDNA aptamers specific to CD63 for the detection of EVs.[168] The ssDNA aptamers adsorbed onto g-C3N4 nanosheets enhanced their intrinsic peroxidase activity and accelerated the oxidation of 3,3′,5,5′- tetramethylbenzidine by H2O2, generating the product with an intense blue color. In the presence of EVs, the ssDNA aptamer bound onto the EVs in a folded structure that had lower affinity for g-C3N4 NSs and could no longer enhance the nanozyme’s peroxidase activity. A light color was therefore yielded (Figure 7a).\nFluorescent imaging is another common visualization technique. Ibsen et al. developed an alternating current electrokinetic (ACE) system for the isolation and fluorescent imaging of EVs based on the different dielectric properties between the EVs and the surrounding plasma.[169] The electric field lines ran between individual microelectrodes and converged onto the edges of the microelectrodes, forming the dielectrophoretic (DEP) high-field regions. The EVs, nucleosomes, and the aggregated proteins were concentrated in the DEP high-field regions around the microelectrode edges, while the cells or larger particles in the samples were concentrated into the DEP low-field areas between the microelectrodes and could be removed by a fluid wash. Fluorescent antibodies specific to the exosomal protein (e.g., CD63) were utilized to immunostain the captured EVs on the ACE device. This device was demonstrated to be able to isolate glioblastoma EVs from undiluted plasma with less than 30 min (Figure 7b). Upconversion nanoparticles (UCNPs) are a new type of fluorescent nanomaterials. When excited by multiple low-energy nearinfrared (NIR) photons, the UCNPs could emit a high-energy photon at the shorter wavelength. The autofluorescence noise produced by the background could therefore be shielded.[170,171] This unique optical property enabled UCNPs to serve as highly sensitive nanoprobes. Wang et al. reported a UCNP-based fluorescent imaging platform for the detection of CTCs.[172] Briefly, the UCNPs core (NaYF4, Y:Yb:Er = 69:30:1) with the diameter of ≈280 nm were attached to Fe3O4 MNPs with an average diameter of 6–8 nm. A thin layer of gold shell (2–3 nm) was grown on the surface of the UCNP–Fe3O4 nanoparticle nanocomposite and anti-EpCAM was conjugated as the probe to recognize CTCs. The magnetic UCNPs were further combined with a silicon-nanowire-based microfluidic system to capture and image CTCs, and were demonstrated to be efficient in the detection and staging of lung cancer (Figure 7c).\nPhotoacoustic imaging was also used to detect CTCs. Hu et al. reported a novel photoacoustic imaging technology for the detecting of CTCs at single cell mL−1 level based on the magneto-optical coupled nanoprobes.[173] The multifunctional nanoprobes were composed of a gold nanorod core, a thin silica shell, multiple iron oxide-based MNPs, and an outer layer of polyethylene glycol (PEG) with a terminal targeting folic acid (Figure 7d). An array of three cone magnets generating a high magnetic field gradient was used to trap the cancer cells labeled with the multifunctional nanoparticles, and a wavelengthtunable laser was used to irradiate the trapped cells. A parallel linear array transducer interfaced with an ultrasound system was used to obtain both the ultrasound and the photoacoustic signals. This system achieved a capture efficiency of ≈67% of the model CTCs and provided imaging with just one pass through the magnetic trapping zone.\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (14 of 25)"
    }, {
      "heading" : "2.3. Reversible Release",
      "text" : "Although enumeration of CTCs or EVs provides preliminary diagnostic-relevant information, the molecular signatures and functional readouts derived from CTCs or EVs, especially the genomic and proteomic profiling of the target liquid biopsies, provide valuable and crucial insight into tumor biology, and give an instruction for effective therapeutic strategies. However, global genomic and proteomic profiling of CTCs has been limited by the small number of the captured CTCs. Therefore, revisable release of the captured cells and EVs is highly needed for unraveling tumor biology and for prognosis evaluation and personalized medicine. The feasible release of the captured targets is quite challenging because the affinity between the captured cells or EVs and surfaces is difficult to break. To address this challenge, “smart” nanostructures or nanomaterials taking advantages of the stimuli-responsive molecules (e.g., thermoresponsive polymer, enzyme-responsive molecule) have been developed. In 2013, on the basis of their previously reported NanoVelcro cell-affinity assay,[42] Tseng and\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (15 of 25)\nco-workers developed a new-generation NanoVelcro Chip with integrated features of capture agent–directed specific capturing and stimulated cell release based on thermally responsive (SiNWS) (Figure 8a).[174] The idea is to covalently graft thermally responsive polymer brushes, poly(N-isopropylacrylamide) (PIPAAm),[175] onto SiNWS. At 37 °C, the biotin groups and hydrophobic domains of these polymers are present on the surfaces of biotin–SiNWS and the capture agent (i.e., biotinylated anti-EpCAM) can be introduced onto the substrates through biotin streptavidin interaction, enabling a highly efficient CTC capture. When the temperature is reduced to 4 °C, the backbones of substrate-grafted PIPAAm undergo conformational changes, leading to an internalization of anti-EpCAM embedded inside the elongated polymer brushes. As a result, the nanosubstrate-immobilized CTCs are effectively released. More than 90% of the captured CTCs can be released, and ≈90% of the released cells remained viable, enabling the downstream cell culture and molecular analysis of the CTCs.\nAnother type of temperature-responsive materials, smart hydrogels that have dynamic topography[178,179] when exposed to temperature stimuli, is introduced as candidate biointerfaces for cell behavior regulation. Wang and co-workers fabricated smart thin hydrogel coatings that can capture targeted cancer cells at physiological temperature and release them at room temperature by simultaneously harnessing surface hydrophobicity and topography.[176] To construct the responsive system, poly(N -isopropylacrylamide) (PNIPAAm) chains that switch between hydrophobic globules above lower critical solution temperature (LCST, ≈32 °C) and stretched hydrophilic coils below LCST were used in their study.[180,181] At 37 °C, the PNIPAAm hydrogel collapses and nanowrinkles appear on the surface owing to heterogeneous shrinkage (Figure 8b, left), which provide more contact sites for cellular protrusions, enhancing the cell–substrate adhesion. To capture cancer cell specifically, biotinylated bovine serum albumin (biotin-BSA) is introduced onto PNIPAAm hydrogel coatings as an anchor via hydrophobic interaction, with subsequent biotinylated anti-EpCAM linked to them, via streptavidin. Thus, CTCs can be specifically captured on the anti-EpCAM-modified hydrogel coatings at 37 °C. When the temperature decreases to 25 °C, the polymer chains\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (16 of 25)\nstretch and the hydrogel coatings reswell, making the surface hydrophilic and those nanowrinkles disappear (Figure 8b, right). Accordingly, the hydrophobic interaction between biotin-BSA and PNIPAAm hydrogel is broken and biotin-BSA detaches from the hydrogel coatings, leading to the release of the captured cells. Therefore, the smart thin hydrogel coatings can capture and release targeted cancer cells by simultaneously tuning surface hydrophobicity and topography responding to surrounding temperature.\nEnzymatic treatment is another workable strategy for smart release of cells. Shen et al. developed a system that is capable of not only capturing nonsmall cell lung cancer (NSCLC) CTCs from blood, but also recovering the nanosubstrate-immobilized NSCLC CTCs upon treatment of nuclease.[130] In their study, DNA-aptamers specific to NSCLC cells were modified with biotin groups and then connected to the streptavidin-mediated SiNWS (Figure 8c). The aptamers can fold into unique secondary or tertiary structures to recognize surface ligands on NSCLC cells with. And then, the genetically engineered endonuclease was employed to recovery of viable NSCLC cells by degrading the SiNWS -grafted DNA aptamer. >80% of A549cell capture efficiency and 0.04–0.3% background signals were obtained. The substrate-immobilized A549 cells were then released via enzyme treatment, with >85% of A549 cell release performance, demonstrating efficient release of the captured CTCs.\nKang and co-workers applied a dual-patterned immunofiltration device for anti-CD63 immunoaffinity-based EV isolation with follow-up recovery of the captured immunotargets by cleavable linker chemistry.[182] In order to enable this function, 3,3ʹ-dithiobis(sulfosuccinimidylpropionate) (DTSSP), which contains a disulfide bond at the middle of the identical arm of the amine-reactive N-hydroxysulfosuccinimide ester, was chosen as a cross-linker. Therefore, this homo-bifunctional cross-linker can be reduced by a reducing agent, dithiothreitol (DTT),[177] which is a water-soluble reducing reagent commonly used in biochemical studies (Figure 8d). Unlike cells, for which the viability after the isolation also needs to be considered, EVs are known to be more stable against changes in chemical or thermal environments,[183] thus, cleavage via reducing reagents can be an appropriate approach for the EV capture and release. The author verified the performance of the device using MCF-7 secreted EVs and found that both the concentration and proportion of EV-sized vesicles were higher than in the samples obtained from the conventional EV isolation kit. The recovery EVs of the clinical sample were also evaluated in terms of cancer-associated surface marker expression, EVsized vesicle concentration, and their proportion. These results demonstrated that the simple and rapid EV recovery technique has huge potential to elucidate the function of EVs in cancer patients and can thus be applied for various EV-based cancer research studies."
    }, {
      "heading" : "2.4. Single-CTC/EV Analysis",
      "text" : "Single-cell/EV analysis is another important application in liquid biopsy. Tumors are heterogenous. Gene and protein profiling are different between the primary and the metastatic\ntumor tissues, and are even different in spatially distinct tumor tissues.[184–186] The expression of marker genes and proteins may change during cancer progression, metastasis and treatment.[8,187] Single-cell/EV analysis enables systematic investigation of tumor heterogeneity, and helps to deep understanding of tumorigenesis, tumor progression, metastasis and the mechanism of drug resistance."
    }, {
      "heading" : "2.4.1. Single-CTC Analysis",
      "text" : "By precisely combining aqueous and oil flows, nanoliter-scaled droplets can be formed to encapsulate single cells for the downstream molecular analysis.[188,189] Posadas and co-workers investigated a series of NanoVelcro chip that combines microfluidic chip with next-generation sequencing (NGS) for the integration of the capture and genetic analysis of CTCs.[190] This chip is capable of capturing CTCs in the whole blood utilizing anti-EpCAM coated silicon nanowire substrates (SiNWS). The nanowire substrate was used to increase the capture efficiency by enhancing the local topographic interactions between the anti-EpCAM coated nanostructures and the nanoscaled cellular surface. To construct the NanoVelcro substrate compatible with laser capture microdissection (LCM) system, PLGA nanofiber (PN) was modified onto the LCM membrane slide (Figure 9a). The chip reached a captured efficiency of 80% of CTCs in the blood with high purity. After CTC capture, methanol was used to preserve the most genomic information, and a modified NanoVelcro Chip coupled with ArcturusXT LCM technology was applied for Exome-Seq. As a result, 25–80% of the targeted exome regions were sequenced with a mean coverage of 29 to 48X. PN-NanoVelcro-LCM system enables large scale detection and gene sequencing of CTCs and provides detailed genetic information for cancer management. The whole-genome amplification for next-generation sequencing has been widely applied for determining genomic variations of rare cells, especially CTCs. However, enough replicates of genomic DNAs for library preparation are required for the traditional protocols. Microfluidic technology can avoid possible contamination and achieve multiple parallel analysis of single DNA. Huang and coworkers recently reported a method based on microdroplet that can achieve the DNA amplification and suppress the amplification bias.[191] Single-cell genomic DNA were divided into a large number (105) of droplets in oil. Each oil only contained a few DNA fragments, and DNA amplification reached saturation (Figure 9b). This method drastically reduced the amplification bias while keeping the accuracy. The emulsion multiple displacement amplification (eMDA) obtained such progress and kept the gain of about 2 × 106 compared to conventional MDA in tube using single human cell as starting materials. The microdroplet technology assisted DNA amplification method and made it possible to simultaneously detect the copy number variations (CNVs) and single-nucleotide variations (SNVs) in an individual human cell, exhibiting significantly improved amplification evenness and accuracy.\nProtein profiling is also critical to understand the behavior and characters of CTCs as genomic profiling may not fully represent the expression of proteins.[193,194] Recently, Sinkala et al. developed a rare-cell, single-cell resolution western blot\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (17 of 25)\n(scWB) microfluidic chip to measure the protein expression in individual CTCs.[192] The chip can integrate with the previously reported CTC-capturing methods, and enable the rapid separation and maximized local concentration of the cell lysis for the subsequent molecular analysis. The scWB device incorporated an array of 50 µm microwells stippled into a 60 µm thin polyacrylamide gel (Figure 9c). This protein panel comprises multi ple proteins and was applied for CTCs isolated from estrogen receptor-positive (ER+) breast cancer patients. Moreover, the scWB technology enabled later-date profiling of new targets with previously lysed single-CTC lysate, which is important to longitudinal studies."
    }, {
      "heading" : "2.4.2. Single-EV Analysis",
      "text" : "Since EVs are secreted not only by the tumor cells, but also by the normal host cells, detection of total EVs from the plasma or serum is not enough to identify the disease-specific EVs. Moreover, tumor heterogeneity may cause variation of the molecular profiles in different EVs. This information can hardly be obtained from the bulk analysis of EVs. Single-EV analysis, in this regard, is of vital significance for the precise diagnosis and analysis of diseases. There are several newly published studies about the single-particle analysis of EVs. Lee et al. reported a multiplexed fluorescent imaging system for the analysis of markers on single EV in glioblastoma.[195] The EVs were biotinylated and subsequently captured on the neutravidin-coated surface. The stationary EVs were sequentially stained by fluorescent antibodies targeting different markers, imaged by the fluorescent microscopy, and then quenched before next cycle of staining (Figure 10a). This technique was able to analyze as many as 11 different marker proteins in a single EV. The image acquisition speed was as fast as <1 s, and >103 EVs could be simultaneously analyzed in a single image. Shen et al. developed a single-EV flow cytometry analysis method based on the target-initiated engineering (TIE) of DNA nanostructures on single EV. A conformation-switchable DNA probe that contained an aptamer domain specific to the marker membrane proteins (e.g., CD63) on EVs and a trigger domain for the initiation of the engineering of DNA nanostructures was developed. The aptamer-target protein interaction triggered the cascaded growth of DNA by hybridization chain reaction (HCR). The yielded HCR products increased the size of the EVs to >500 nm, and therefore enabled the detection of single EV by the traditional flow cytometry (Figure 10b).[196] This technique was successfully used to analyze the expression of proteins on single EV from breast cancer cell lines and would be beneficial for the screening of the molecular markers on EVs.\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (18 of 25)"
    }, {
      "heading" : "3. Multifunctional and Integrated Nanotechnology-Based Biodetection",
      "text" : "Since tumorigenesis and cancer progression involve complicated changes in different pathways, single biomarker may not be enough to represent the disease status. Parallel detection and analysis of multiple biomarkers is essential for integral monitoring of cancer progress and precision medicine.[197,198] Microfluidics, characterized by the engineered manipulation of fluids at the microscale, enable minimum sample consumption, enhanced sensitivity and purity, fast speed, and high throughput analysis, and therefore provide versatile platforms for liquid biopsy.[199–202] In this section, recent progress in microfluidics and their application as multifunctional and integrated technologies in biological detection are discussed. Microfluidic tools, due to its small physical size and integration of functionality, have served as a promising tool for the capture and analysis of CTCs and EVs.[35,54,202–204] Microfluidic technology not only offers automatic, versatile and high throughput detection and the downstream molecular analysis of CTCs and EVs, but also provides opportunities for the culture of the isolated CTCs. Due to these advantages, microfluidic devices hold great potential in the liquid biopsy market.[38,205–209] Early microfluidic devices were mainly based on microsized structures, either coated with probes or not, for the isolation of tumor cells. The classical examples were antibody-coated micropost chip,[56] the herringbone-bone (HB-chip) in which the microvortex was introduced into the microchannels by altering the ratio of height, chevron dimensions and periodicity of the channels,[210] the micropillar-based chip for the isolation of CTCs or CTC\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (19 of 25)\nclusters based on the deterministic displacement (DLD) theory that particles with larger size interacted more with the micropillars as a result of the hydrodynamic in continuous flow,[211,212] the acoustic-based microfluidic chip that distinguished cells based on their size, density, compressibility, and other physical characters,[213] and so on. These microtechnology-based chips and devices have experienced evolution to expand their application in the isolation of nanosized biomarkers. For example, to promote and application of micropillars in the detection of nanosized biomarkers such as EVs, the gap size of the pillar structures was decreased to 25–235 nm to construct nanopillars for the separation of EVs based on DLD theory (Figure 11a).[214] Nanostructures and nanomaterials (e.g., porous silicon nanowires) were also combined with the micropillars for the capture nanosized EVs.[215] Also, in the newly designed EVHB-Chip, the tumor-specific antibody-coated herringbone microfluidic was combined with thermally responsive gelatin-based nanostructured substrate that enabled EVs release (Figure 11b).[216] After optimizing the flow rate and the PEG linker that immobilized antibodies to the nanostructured interface, over tenfold increase in tumor-derived EV enrichment ratios were observed when compared to the gold standard method UC. The author demonstrated the clinical potential of the device by identifying EGFRvIII mutation in serum EVs from glioblastoma patients. Acoustic technology has also been used for EV isolation due to its contact-free and undamaged advantages. Researchers in Massachusetts General Hospital have designed an acoustic purification chip for EVs isolation and achieved high resolution in cell culture medium and microvesicles (MVs) in red blood cell products.[170] More recently, Wu et al. optimized this device and presented a chip consisting of two acoustic modules: cell-removal module and EV-isolation module (Figure 11c). Combining these two modules, EVs can be isolated directly from the whole blood with a purity of 99.999%. This isolating method is undamaged, label-free and can fairly preserve the integrity of EVs.[217] Another novel method based on physical isolation were developed by Sun’s group, with a viscoelasticity-based isolation chip (Figure 11d).[218] This viscoelastic microfluidic chip has been demonstrated as a simple, label-free and efficient technology to separate tumor cells[219] and blood cells,[220] relying on particle migration caused by size-dependent elastic lift forces in a viscoelastic medium. By translating and optimizing this method to\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (20 of 25)\ndifferentiate nanoscale particles with different sizes, EVs were continuously separated from large EVs from cell culture medium or serum, with a purity of 90% and a recovery of 80%.[218]"
    }, {
      "heading" : "4. Standardization of Nanotechnology-Based Biodetection",
      "text" : "The rapid progress in nanotechnologies offers great opportunities in the biological detection. However, they also bring great challenges in the accuracy and reproducibility of the results due to the complexity of nanotechnologies. Each material or technique has its own applicable range, and can achieve good performance only under certain conditions. Even for the same nanomaterial and nanotechnology, variations in the manufacture process of the materials and devices, the operating procedures, the detecting equipment, and the operator-induced errors may cause discrepancies in the results.[221] From Nature’s survey of 1576 researchers who took a brief online questionnaire on the reproducibility in research, more than 70% of the researchers have tried and failed to reproduce the results from other scientists, and more than half have failed to reproduce their own experiments.[222] One reason for the low reproducibility is due to the lack of unified standards. Therefore, there is strong need for the standardization of nanotechnologies to obtain a convincing and reproducible results.\nNowadays, standardization of nanotechnology-based biological detection is still at the initial stage, where the fundamental framework has just been established. A technical committee of nanotechnologies named the International Organization for Standardization (ISO/TC229) was founded in 2005, and has published 65 international standards in the field of terminology and nomenclature, measurement and characterization, health, safety and environmental aspects of nanotechnologies, material specifications, as well as products and applications. For example, these newly developed nanomaterials and nanodevices need a complete set of calibration and standards before come into use. In addition, the comparison of them with the existing clinical “gold standard” should also be discussed.\nDespite differences and variation in different nanomaterials and nanotechnologies, several essential components of standardization should be taken into consideration. Herein, we provide an opinion of how to establish the standards and discuss the application principle of the standards in the nanotechnology-based biological detection. These standards and discussion would permit interlaboratory reproducibility and offer criterion for their clinical application in the near future. First, diverse characterization methods are required to specify the features and properties of the nanomaterials and nanodevices, ensuring the manufacture reproducibility. For example, fully characterization of the physical and chemical properties of the nanomaterials should be performed. For nanodevices, more precise characterization and quality control should be performed for the quality control of their standard nanostructures and interfaces. Secondly, as a detection tool, it is desired that the nanotechnology-based liquid biopsy is biology-friendly and nontoxic. Thirdly, unified parameters and protocols are also required to obtain reliable and convincing results. The interpretation of the results obtained from measurements is\nanother important matter among the whole detection process. Last but not the least, the comparison of the novel nanotechnologies with the “gold standards” that are traditionally used should also be considered. For example, in the study of the microbead-based flow cytometry analysis of EV, EV-based HER2 phenotyping of breast cancer was confirmed and consistent with the traditionally used immunohistochemistry staining of the cancer tissues, suggesting the potential of this novel method for HER2 phenotyping in clinical applications."
    }, {
      "heading" : "5. Outlook and Concluding Remarks",
      "text" : "Nanotechnologies have hold significant position in liquid biopsy and have experience great progress in the recent decades. Nanotechnologies that were involved in biological detection have evolved from individual nanomaterial or nanostructure to the integrated nanobased platforms and devices, enabling multifunctional and high-throughput analysis of CTCs and EVs with high sensitivity and specificity. Novel sensing and visualization methods and techniques have also been developed for the noninvasive, rapid, and readable detection and molecular analysis of CTCs and EVs. These improvements promote the application of nanotechnology-based liquid biopsy in the early diagnosis, real-time monitoring, and prognosis evaluation of diseases including cancer. Zhang et al. reported a nanointerfaced microfluidic EV (nano-IMEX) platform based on the coating of GO and polydopamine for ultrasensitive EV detection,[107] and successfully applied this novel method in distinguishing ovarian cancer patients from the healthy controls directly from the unprocessed plasma samples of the minimal volume (2 µL). Hu and co-workers described a nanoparticleenhanced scattering assay that enabled the detection of plasma EphA2-EV with high sensitivity and specificity.[49] The measured levels of plasma EphA2-EV were significantly higher in pancreatic cancer patients than in pancreatitis and healthy subjects. Changes in the level of EphA2-EV were also found between preand post-therapy, suggesting the significance of this method in monitoring therapy response. A novel SPR-based assay named nanoplasmonic EV sensor[146] was developed based on the optical transmission through arrays of periodic nanoholes patterned in gold films for EV protein analyses.[149] Yang and co-workers identified a PDACEV signature with five markers (EGFR, EPCAM, MUC1, GPC1, and WNT2), and determined key protein profiles of EVs in 135 patients undergoing surgery for pancreatic pathologies. Applying the above PDACEV signature to the patients, they showed an overall sensitivity of 86% for detecting PDAC and a specificity of 81% for differentiating PDAC from other pancreatic diseases. Using nPLEX sensor, the PDACEV signature of EVs offered higher sensitivity, specificity, and accuracy than single-EV marker analysis or the traditional serum marker (CA 19-9) for the diagnosis of PDAC.[223] These successful applications in the clinic revealed the strong potential of nanotechnology-based approaches as promising detection tools in noninvasively early diagnosis, disease monitoring, treatment response evaluation, and prognosis predication of cancer patients.\nHowever, despite the progressive advances, there is a long way to go before the wide application of nanotechnology-based\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (21 of 25)\nliquid biopsy as a routine test in clinical applications. One major challenge for large-scale clinical use is the lack of standardization to normalization. The interdisciplinary character of nanotechnology, different technological and measurement approaches and methods, different application fields, and different operating laboratories may lead to the disconnection and variation in the measured results. Standardization is the prerequisite for obtaining convincing and reproducible results. Standardization for the manufacture and characterization of the nanomaterials and nanostructures, the protocols for sample preparation and biological detection, and the reasonable method for data reporting will benefit to the real application of liquid biopsy in the clinic. Advanced development of the metrological measurements, standardized methods, and certified reference materials of nanotechnology is a guarantee of the practical applications of the nanobased detections. In recent years, although a plenty of standards have been published by several international organizations and have been successfully applied in some biological detection methods, they are far from enough. Global standardization should be looked at with a longterm perspective, and progress toward the final goal requires a steady and productive pace. The international collaboration and participation from national institutions, academia, and industry are essential for efficiently promoting standardization and accelerating the transition of basic nanoscale technologies into clinical applications.\nConflict of Interest The authors declare no conflict of interest.\nKeywords biological detection, circulating tumor cells, extracellular vesicles, liquid biopsy, nanotechnology\nReceived: August 16, 2018 Revised: October 29, 2018\nPublished online:\n[1] A. Diamantis, E. Magiorkinis, H. Koutselini, Folia Histochem. Cytobiol. 2009, 47, 191. [2] C. D. Roberson, S. Atay, C. Gercel-Taylor, D. D. Taylor, Cancer Biomarkers 2010, 8, 281. [3] M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, N. Engl. J. Med. 2005, 353, 1659. [4] G. J. Riely, W. Pao, D. Pham, A. R. Li, N. Rizvi, E. S. Venkatraman, M. F. Zakowski, M. G. Kris, M. Ladanyi, V. A. Miller, Clin. Cancer Res. 2006, 12, 839. [5] W. J. Frable, Hum. Pathol. 1983, 14, 9. [6] E. Munzone, F. Nole, A. Goldhirsch, E. Botteri, A. Esposito,\nL. Zorzino, G. Curigliano, I. Minchella, L. Adamoli, M. C. Cassatella, C. Casadio, M. T. Sandri, Clin. Breast Cancer 2010, 10, 392. [7] V. Guarneri, S. Giovannelli, G. Ficarra, S. Bettelli, A. Maiorana, F. Piacentini, E. Barbieri, M. V. Dieci, R. D’Amico, G. Jovic, P. Conte, Oncologist 2008, 13, 838.\n[8] M. Gerlinger, A. J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, P. Tarpey, N. Engl. J. Med. 2012, 366, 883. [9] C. Alix-Panabières, H. Schwarzenbach, K. Pantel, Annu. Rev. Med. 2012, 63, 199. [10] T. Ashworth, Aust. Med. J. 1869, 14, 146. [11] C. L. Chaffer, R. A. Weinberg, Science 2011, 331, 1559. [12] C. Alix-Panabières, K. Pantel, Clin. Chem. 2013, 59, 110. [13] I. Baccelli, A. Schneeweiss, S. Riethdorf, A. Stenzinger, A. Schillert,\nV. Vogel, C. Klein, M. Saini, T. Bauerle, M. Wallwiener, T. Holland-Letz, T. Hofner, M. Sprick, M. Scharpff, F. Marme, H. P. Sinn, K. Pantel, W. Weichert, A. Trumpp, Nat. Biotechnol. 2013, 31, 539. [14] P. Mandel, P. Metais, C. R. Acad. Sci. Paris 1948, 142, 241. [15] G. D. Sorenson, D. M. Pribish, F. H. Valone, V. A. Memoli,\nD. J. Bzik, S. L. Yao, Cancer Epidemiol., Biomarkers Prev. 1994, 3, 67. [16] H. Nawroz, W. Koch, P. Anker, M. Stroun, D. Sidransky, Nat. Med.\n1996, 2, 1035. [17] E. G. Trams, C. J. Lauter, N. Salem Jr., U. Heine, Biochim. Biophys.\nActa, Biomembr. 1981, 645, 63. [18] G. Raposo, H. W. Nijman, W. Stoorvogel, R. Liejendekker,\nC. V. Harding, C. J. Melief, H. J. Geuze, J. Exp. Med. 1996, 183, 1161. [19] L. Zitvogel, A. Regnault, A. Lozier, J. Wolfers, C. Flament, D. Tenza,\nP. Ricciardi-Castagnoli, G. Raposo, S. Amigorena, Nat. Med. 1998, 4, 594. [20] N. Chaput, C. Thery, Semin. Immunopathol. 2011, 33, 419. [21] C. Thery, L. Zitvogel, S. Amigorena, Nat. Rev. Immunol. 2002, 2, 569. [22] S. E. Andaloussi, I. Mäger, X. O. Breakefield, M. J. Wood, Nat. Rev.\nDrug Discovery 2013, 12, 347. [23] M. Colombo, G. Raposo, C. Théry, Annu. Rev. Cell Dev. Biol. 2014,\n30, 255. [24] C. Alix-Panabieres, K. Pantel, Cancer Discovery 2016, 6, 479. [25] T. Lener, M. Gimona, L. Aigner, V. Borger, E. Buzas, G. Camussi,\nN. Chaput, D. Chatterjee, F. A. Court, H. A. Del Portillo, L. O’Driscoll, S. Fais, J. M. Falcon-Perez, U. Felderhoff-Mueser, L. Fraile, Y. S. Gho, A. Gorgens, R. C. Gupta, A. Hendrix, D. M. Hermann, A. F. Hill, F. Hochberg, P. A. Horn, D. de Kleijn, L. Kordelas, B. W. Kramer, E. M. Kramer-Albers, S. Laner-Plamberger, S. Laitinen, T. Leonardi, M. J. Lorenowicz, S. K. Lim, J. Lotvall, C. A. Maguire, A. Marcilla, I. Nazarenko, T. Ochiya, T. Patel, S. Pedersen, G. Pocsfalvi, S. Pluchino, P. Quesenberry, I. G. Reischl, F. J. Rivera, R. Sanzenbacher, K. Schallmoser, I. Slaper-Cortenbach, D. Strunk, T. Tonn, P. Vader, B. W. van Balkom, M. Wauben, S. E. Andaloussi, C. Thery, E. Rohde, B. Giebel, J. Extracell. Vesicles 2015, 4, 30087. [26] E. Crowley, F. Di Nicolantonio, F. Loupakis, A. Bardelli, Nat. Rev. Clin. Oncol. 2013, 10, 472. [27] W. Zhang, W. Xia, Z. Lv, C. Ni, Y. Xin, L. Yang, Cell. Physiol. Biochem. 2017, 411, 755. [28] I. Y. Wong, S. N. Bhatia, M. Toner, Genes Dev. 2013, 27, 2397. [29] G. M. Whitesides, Nat. Biotechnol. 2003, 21, 1161. [30] V. Plaks, C. D. Koopman, Z. Werb, Science 2013, 341, 1186. [31] S. C. Williams, Proc. Natl. Acad. Sci. USA 2013, 110, 4861. [32] W. S. Tsai, J. S. Chen, H. J. Shao, J. C. Wu, J. M. Lai, S. H. Lu,\nT. F. Hung, Y. C. Chiu, J. F. You, P. S. Hsieh, C. Y. Yeh, H. Y. Hung, S. F. Chiang, G. P. Lin, R. Tang, Y. C. Chang, Sci. Rep. 2016, 6, 24517. [33] N. V. Jordan, A. Bardia, B. S. Wittner, C. Benes, M. Ligorio, Y. Zheng, M. Yu, T. K. Sundaresan, J. A. Licausi, R. Desai, Nature 2016, 537, 102. [34] J. G. Lohr, V. A. Adalsteinsson, K. Cibulskis, A. D. Choudhury, M. Rosenberg, P. Cruz-Gordillo, J. M. Francis, C.-Z. Zhang, A. K. Shalek, R. Satija, Nat. Biotechnol. 2014, 32, 479. [35] W. Qian, Y. Zhang, W. Chen, Small 2015, 11, 3850. [36] E. Sollier, D. E. Go, J. Che, D. R. Gossett, S. O’Byrne, W. M. Weaver,\nN. Kummer, M. Rettig, J. Goldman, N. Nickols, S. McCloskey, R. P. Kulkarni, D. Di Carlo, Lab Chip 2014, 14, 63.\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (22 of 25)\n[37] H. K. Lin, S. Zheng, A. J. Williams, M. Balic, S. Groshen, H. I. Scher, M. Fleisher, W. Stadler, R. H. Datar, Y. C. Tai, R. J. Cote, Clin. Cancer Res. 2010, 16, 5011. [38] L. S. Lim, M. Hu, M. C. Huang, W. C. Cheong, A. T. Gan, X. L. Looi, S. M. Leong, E. S. Koay, M. H. Li, Lab Chip 2012, 12, 4388. [39] M. Hosokawa, T. Hayata, Y. Fukuda, A. Arakaki, T. Yoshino, T. Tanaka, T. Matsunaga, Anal. Chem. 2010, 82, 6629. [40] W. Chen, S. Weng, F. Zhang, S. Allen, X. Li, L. Bao, R. H. Lam, J. A. Macoska, S. D. Merajver, J. Fu, ACS Nano 2013, 7, 566. [41] S. S. Kanwar, C. J. Dunlay, D. M. Simeone, S. Nagrath, Lab Chip 2014, 14, 1891. [42] S. Wang, H. Wang, J. Jiao, K. J. Chen, G. E. Owens, K. Kamei, J. Sun, D. J. Sherman, C. P. Behrenbruch, H. Wu, H. R. Tseng, Angew. Chem., Int. Ed. 2009, 48, 8970. [43] J. Peng, Q. Zhao, W. Zheng, W. Li, P. Li, L. Zhu, X. Liu, B. Shao, H. Li, C. Wang, Y. Yang, ACS Appl. Mater. Interfaces 2017, 9, 18423. [44] G. K. Joshi, S. Deitz-McElyea, T. Liyanage, K. Lawrence, S. Mali, R. Sardar, M. Korc, ACS Nano 2015, 9, 11075. [45] U. Dharmasiri, S. Balamurugan, A. A. Adams, P. I. Okagbare, A. Obubuafo, S. A. Soper, Electrophoresis 2009, 30, 3289. [46] G. A. Lopez, M. C. Estevez, M. Soler, L. M. Lechuga, Nanophotonics 2017, 6, 123. [47] O. Tokel, F. Inci, U. Demirci, Chem. Rev. 2014, 114, 5728. [48] J. Wang, Biosens. Bioelectron. 2006, 21, 1887. [49] K. Liang, F. Liu, J. Fan, D. Sun, C. Liu, C. J. Lyon, D. W. Bernard,\nY. Li, K. Yokoi, M. H. Katz, E. J. Koay, Z. Zhao, Y. Hu, Nat. Biomed. Eng. 2017, 1. [50] H. Min, S. M. Jo, H. S. Kim, Small 2015, 11, 2536. [51] H. Shao, J. Chung, K. Lee, L. Balaj, C. Min, B. S. Carter,\nF. H. Hochberg, X. O. Breakefield, H. Lee, R. Weissleder, Nat. Commun. 2015, 6, 6999. [52] S. Sestini, M. Boeri, A. Marchiano, G. Pelosi, C. Galeone, C. Verri, P. Suatoni, N. Sverzellati, C. La Vecchia, G. Sozzi, Oncotarget 2015, 6, 32868. [53] Y. T. Lu, L. Zhao, Q. Shen, M. A. Garcia, D. Wu, S. Hou, M. Song, X. Xu, W. H. Ouyang, W. W. Ouyang, J. Lichterman, Z. Luo, X. Xuan, J. Huang, L. W. Chung, M. Rettig, H. R. Tseng, C. Shao, E. M. Posadas, Methods 2013, 64, 144. [54] H. Shao, J. Chung, L. Balaj, A. Charest, D. D. Bigner, B. S. Carter, F. H. Hochberg, X. O. Breakefield, R. Weissleder, H. Lee, Nat. Med. 2012, 18, 1835. [55] K. Boriachek, M. N. Islam, V. Gopalan, A. K. Lam, N.-T. Nguyen, M. J. A. Shiddiky, Analyst 2017, 142, 2211. [56] S. Nagrath, L. V. Sequist, S. Maheswaran, D. W. Bell, D. Irimia, L. Ulkus, M. R. Smith, E. L. Kwak, S. Digumarthy, A. Muzikansky, P. Ryan, U. J. Balis, R. G. Tompkins, D. A. Haber, M. Toner, Nature 2007, 450, 1235. [57] J. P. Gleghorn, E. D. Pratt, D. Denning, H. Liu, N. H. Bander, S. T. Tagawa, D. M. Nanus, P. A. Giannakakou, B. J. Kirby, Lab Chip 2010, 10, 27. [58] L. Bai, Y. Du, J. Peng, Y. Liu, Y. Wang, Y. Yang, C. Wang, J. Mater. Chem. B 2014, 2, 4080. [59] X. Li, H. Guo, H. Duan, Y. Yang, J. Meng, J. Liu, C. Wang, H. Xu, Sci. Rep. 2015, 5, 16228. [60] W. Sheng, T. Chen, R. Kamath, X. Xiong, W. Tan, Z. H. Fan, Anal. Chem. 2012, 84, 4199. [61] Y. Wan, Y. T. Kim, N. Li, S. K. Cho, R. Bachoo, A. D. Ellington, S. M. Iqbal, Cancer Res. 2010, 70, 9371. [62] X. R. Xia, N. A. Monteiro-Riviere, J. E. Riviere, Nat. Nanotechnol. 2010, 5, 671. [63] M. A. Dobrovolskaia, S. E. McNeil, Nat. Nanotechnol. 2007, 2, 469. [64] S. L. Stott, R. J. Lee, S. Nagrath, M. Yu, D. T. Miyamoto, L. Ulkus, E. J. Inserra, M. Ulman, S. Springer, Z. Nakamura, A. L. Moore, D. I. Tsukrov, M. E. Kempner, D. M. Dahl, C.-L. Wu, A. J. Iafrate,\nM. R. Smith, R. G. Tompkins, L. V. Sequist, M. Toner, D. A. Haber, S. Maheswaran, Sci. Transl. Med. 2010, 2, 25ra23. [65] P. T. H. Went, A. Lugli, S. Meier, M. Bundi, M. Mirlacher, G. Sauter, S. Dirnhofer, Hum. Pathol. 2004, 35, 122. [66] M. Cristofanilli, G. T. Budd, M. J. Ellis, A. Stopeck, J. Matera, M. C. Miller, J. M. Reuben, G. V. Doyle, W. J. Allard, L. W. Terstappen, N. Engl. J. Med. 2004, 351, 781. [67] W. A. Osta, Y. Chen, K. Mikhitarian, M. Mitas, M. Salem, Y. A. Hannun, D. J. Cole, W. E. Gillanders, Cancer Res. 2004, 64, 5818. [68] O. Gires, C. A. Klein, P. A. Baeuerle, Nat. Rev. Cancer 2009, 9, 143. [69] Y. Mi, K. Li, Y. Liu, K. Y. Pu, B. Liu, S. S. Feng, Biomaterials 2011,\n32, 8226. [70] A. Ghosh, W. D. W. Heston, J. Cell. Biochem. 2004, 91, 528. [71] J. M. Chan, M. J. Stampfer, E. Giovannucci, P. H. Gann, J. Ma,\nP. Wilkinson, C. H. Hennekens, M. Pollak, Science 1998, 279, 563. [72] W. Li, B. Shao, C. Liu, H. Wang, W. Zheng, W. Kong, X. Liu, G. Xu,\nC. Wang, H. Li, Small Methods 2, 2018, 1800122. [73] Y. Li, Q. Lu, H. Liu, J. Wang, P. Zhang, H. Liang, L. Jiang, S. Wang,\nAdv. Mater. 2015, 27, 6848. [74] H. Xu, Z. P. Aguilar, L. Yang, M. Kuang, H. Duan, Y. Xiong, H. Wei,\nA. Wang, Biomaterials 2011, 32, 9758. [75] F. Inci, C. Filippini, M. Baday, M. O. Ozen, S. Calamak,\nN. G. Durmus, S. Wang, E. Hanhauser, K. S. Hobbs, F. Juillard, P. P. Kuang, M. L. Vetter, M. Carocci, H. S. Yamamoto, Y. Takagi, U. H. Yildiz, D. Akin, D. R. Wesemann, A. Singhal, P. L. Yang, M. L. Nibert, R. N. Fichorova, D. T. Lau, T. J. Henrich, K. M. Kaye, S. C. Schachter, D. R. Kuritzkes, L. M. Steinmetz, S. S. Gambhir, R. W. Davis, U. Demirci, Proc. Natl. Acad. Sci. USA 2015, 112, E4354. [76] S. Ueno, S. Yoshida, A. Mondal, K. Nishina, M. Koyama, I. Sakata, K. Miura, Y. Hayashi, N. Nemoto, K. Nishigaki, T. Sakai, Proc. Natl. Acad. Sci. USA 2012, 109, 11121. [77] Y. Wang, W. Shi, W. Song, L. Wang, X. Liu, J. Chen, R. Huang, J. Mater. Chem. 2012, 22, 14608. [78] S. Aggarwal, S. Janssen, R. M. Wadkins, J. L. Harden, S. R. Denmeade, Biomaterials 2005, 26, 6077. [79] H.-S. Cho, K. Mason, K. X. Ramyar, A. M. Stanley, S. B. Gabelli, D. W. Denney Jr., D. J. Leahy, Nature 2003, 421, 756. [80] Q. Zhou, A. Rahimian, K. Son, D. S. Shin, T. Patel, A. Revzin, Methods 2016, 97, 88. [81] G. Zheng, F. Patolsky, Y. Cui, W. U. Wang, C. M. Lieber, Nat. Biotechnol. 2005, 23, 1294. [82] B. P. Viraka Nellore, R. Kanchanapally, A. Pramanik, S. S. Sinha, S. R. Chavva, A. Hamme, 2nd, P. C. Ray, Bioconjugate Chem. 2015, 26, 235. [83] Z. A. Nima, M. Mahmood, Y. Xu, T. Mustafa, F. Watanabe, D. A. Nedosekin, M. A. Juratli, T. Fahmi, E. I. Galanzha, J. P. Nolan, A. G. Basnakian, V. P. Zharov, A. S. Biris, Sci. Rep. 2015, 4, 4752. [84] C. H. Choi, L. Hao, S. P. Narayan, E. Auyeung, C. A. Mirkin, Proc. Natl. Acad. Sci. USA 2013, 110, 7625. [85] D. S. Seferos, D. A. Giljohann, H. D. Hill, A. E. Prigodich, C. A. Mirkin, J. Am. Chem. Soc. 2007, 129, 15477. [86] T. L. Halo, K. M. McMahon, N. L. Angeloni, Y. Xu, W. Wang, A. B. Chinen, D. Malin, E. Strekalova, V. L. Cryns, C. Cheng, Proc. Natl. Acad. Sci. USA 2014, 111, 17104. [87] Y. Wan, G. Cheng, X. Liu, S. J. Hao, M. Nisic, C. D. Zhu, Y. Q. Xia, W. Q. Li, Z. G. Wang, W. L. Zhang, S. J. Rice, A. Sebastian, I. Albert, C. P. Belani, S. Y. Zheng, Nat. Biomed. Eng. 2017, 1, 0058. [88] E. I. Galanzha, E. V. Shashkov, T. Kelly, J. W. Kim, L. Yang, V. P. Zharov, Nat. Nanotechnol. 2009, 4, 855. [89] S. Bamrungsap, T. Chen, M. I. Shukoor, Z. Chen, K. Sefah, Y. Chen, W. Tan, ACS Nano 2012, 6, 3974. [90] S. J. Cohen, C. Punt, N. Iannotti, B. H. Saidman, K. D. Sabbath, N. Y. Gabrail, J. Picus, M. Morse, E. Mitchell, M. C. Miller, J. Clin. Oncol. 2008, 26, 3213.\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (23 of 25)\n[91] S. Riethdorf, H. Fritsche, V. Muller, T. Rau, C. Schindlbeck, B. Rack, W. Janni, C. Coith, K. Beck, F. Janicke, S. Jackson, T. Gornet, M. Cristofanilli, K. Pantel, Clin. Cancer Res. 2007, 13, 920. [92] C.-Y. Wen, L.-L. Wu, Z.-L. Zhang, Y.-L. Liu, S.-Z. Wei, J. Hu, M. Tang, E.-Z. Sun, Y.-P. Gong, J. Yu, ACS Nano 2014, 8, 941. [93] Z. Chen, G. Hong, H. Wang, K. Welsher, S. M. Tabakman, S. P. Sherlock, J. T. Robinson, Y. Liang, H. Dai, ACS Nano 2012, 6, 1094. [94] J. B. Haun, N. K. Devaraj, S. A. Hilderbrand, H. Lee, R. Weissleder, Nat. Nanotechnol. 2010, 5, 660. [95] A. P. Johnston, M. M. Kamphuis, G. K. Such, A. M. Scott, E. C. Nice, J. K. Heath, F. Caruso, ACS Nano 2012, 6, 6667. [96] K. Xiong, W. Wei, Y. Jin, S. Wang, D. Zhao, S. Wang, X. Gao, C. Qiao, H. Yue, G. Ma, H. Y. Xie, Adv. Mater. 2016, 28, 7929. [97] P. L. Rodriguez, T. Harada, D. A. Christian, D. A. Pantano, R. K. Tsai, D. E. Discher, Science 2013, 339, 971. [98] L. Rao, Q.-F. Meng, Q. Huang, Z. Wang, G.-T. Yu, A. Li, W. Ma, N. Zhang, S.-S. Guo, X.-Z. Zhao, K. Liu, Y. Yuan, W. Liu, Adv. Funct. Mater. 2018, 28, 1803531. [99] M. J. Shiddiky, S. Rauf, P. H. Kithva, M. Trau, Biosens. Bioelectron. 2012, 35, 251. [100] A. Neely, C. Perry, B. Varisli, A. K. Singh, T. Arbneshi, D. Senapati, J. R. Kalluri, P. C. Ray, ACS Nano 2009, 3, 2834. [101] G. S. Park, H. Kwon, D. W. Kwak, S. Y. Park, M. Kim, J. H. Lee, H. Han, S. Heo, X. S. Li, J. H. Lee, Y. H. Kim, J. G. Lee, W. Yang, H. Y. Cho, S. K. Kim, K. Kim, Nano Lett. 2012, 12, 1638. [102] A. Thapa, D. C. Miller, T. J. Webster, K. M. Haberstroh, Biomaterials 2003, 24, 2915. [103] D. C. Miller, A. Thapa, K. M. Haberstroh, T. J. Webster, Biomaterials 2004, 25, 53. [104] Y. Wan, M. A. Mahmood, N. Li, P. B. Allen, Y. T. Kim, R. Bachoo, A. D. Ellington, S. M. Iqbal, Cancer 2012, 118, 1145. [105] H. J. Yoon, T. H. Kim, Z. Zhang, E. Azizi, T. M. Pham, C. Paoletti, J. Lin, N. Ramnath, M. S. Wicha, D. F. Hayes, D. M. Simeone, S. Nagrath, Nat. Nanotechnol. 2013, 8, 735. [106] C. Pang, J. H. Koo, A. Nguyen, J. M. Caves, M. G. Kim, A. Chortos, K. Kim, P. J. Wang, J. B. Tok, Z. Bao, Adv. Mater. 2015, 27, 634. [107] P. Zhang, M. He, Y. Zeng, Lab Chip 2016, 16, 3033. [108] H. Shafiee, W. Asghar, F. Inci, M. Yuksekkaya, M. Jahangir,\nM. H. Zhang, N. G. Durmus, U. A. Gurkan, D. R. Kuritzkes, U. Demirci, Sci. Rep. 2015, 5, 8719. [109] H. W. Hou, M. E. Warkiani, B. L. Khoo, Z. R. Li, R. A. Soo, D. S. Tan, W. T. Lim, J. Han, A. A. Bhagat, C. T. Lim, Sci. Rep. 2013, 3, 1259. [110] H.-S. Moon, K. Kwon, S.-I. Kim, H. Han, J. Sohn, S. Lee, H.-I. Jung, Lab Chip 2011, 11, 1118. [111] P. Paterlini-Brechot, N. L. Benali, Cancer Lett. 2007, 253, 180. [112] W. Asghar, Y. Wan, A. Ilyas, R. Bachoo, Y. T. Kim, S. M. Iqbal, Lab\nChip 2012, 12, 2345. [113] H. Mohamed, M. Murray, J. N. Turner, M. Caggana, J. Chromatogr.\nA 2009, 1216, 8289. [114] A. Lee, J. Park, M. Lim, V. Sunkara, S. Y. Kim, G. H. Kim,\nM. H. Kim, Y. K. Cho, Anal. Chem. 2014, 86, 11349. [115] F. Liu, O. Vermesh, V. Mani, T. J. Ge, S. J. Madsen, A. Sabour,\nE. C. Hsu, G. Gowrishankar, M. Kanada, J. V. Jokerst, R. G. Sierra, E. Chang, K. Lau, K. Sridhar, A. Bermudez, S. J. Pitteri, T. Stoyanova, R. Sinclair, V. S. Nair, S. S. Gambhir, U. Demirci, ACS Nano 2017, 11, 10712. [116] C. Théry, S. Amigorena, G. Raposo, A. Clayton, Curr. Protoc.Cell Biol. 2006, 30, 3, 221. [117] D. W. Greening, R. Xu, H. Ji, B. J. Tauro, R. J. Simpson, in Proteomic Profiling (Ed: A. Posch), Springer, New York 2015, p. 179. [118] C. J. Bettinger, R. Langer, J. T. Borenstein, Angew. Chem., Int. Ed. 2009, 48, 5406. [119] X. Liu, S. Wang, Chem. Soc. Rev. 2014, 43, 2385.\n[120] S. Wang, K. Liu, J. Liu, Z. T. Yu, X. Xu, L. Zhao, T. Lee, E. K. Lee, J. Reiss, Y. K. Lee, L. W. Chung, J. Huang, M. Rettig, D. Seligson, K. N. Duraiswamy, C. K. Shen, H. R. Tseng, Angew. Chem., Int. Ed. 2011, 50, 3084. [121] S. K. Lee, D. J. Kim, G. Lee, G. S. Kim, M. Kwak, R. Fan, Biosens. Bioelectron. 2014, 54, 181. [122] J. M. Dang, K. W. Leong, Adv. Mater. 2007, 19, 2775. [123] N. Zhang, Y. Deng, Q. Tai, B. Cheng, L. Zhao, Q. Shen, R. He,\nL. Hong, W. Liu, S. Guo, K. Liu, H. R. Tseng, B. Xiong, X. Z. Zhao, Adv. Mater. 2012, 24, 2756. [124] H. Pei, N. Lu, Y. Wen, S. Song, Y. Liu, H. Yan, C. Fan, Adv. Mater. 2010, 22, 4754. [125] M. Lin, J. F. Chen, Y. T. Lu, Y. Zhang, J. Song, S. Hou, Z. Ke, H. R. Tseng, Acc. Chem. Res. 2014, 47, 2941. [126] H. Liu, Y. Li, K. Sun, J. Fan, P. Zhang, J. Meng, S. Wang, L. Jiang, J. Am. Chem. Soc. 2013, 135, 7603. [127] S. Wang, L. Zhang, S. Wan, S. Cansiz, C. Cui, Y. Liu, R. Cai, C. Hong, I. T. Teng, M. Shi, Y. Wu, Y. Dong, W. Tan, ACS Nano 2017, 11, 3943. [128] J. Sekine, S. C. Luo, S. Wang, B. Zhu, H. R. Tseng, H. H. Yu, Adv. Mater. 2011, 23, 4788. [129] S. Hou, L. Zhao, Q. Shen, J. Yu, C. Ng, X. Kong, D. Wu, M. Song, X. Shi, X. Xu, W. H. OuYang, R. He, X. Z. Zhao, T. Lee, F. C. Brunicardi, M. A. Garcia, A. Ribas, R. S. Lo, H. R. Tseng, Angew. Chem., Int. Ed. 2013, 52, 3379. [130] Q. Shen, L. Xu, L. Zhao, D. Wu, Y. Fan, Y. Zhou, W. H. Ouyang, X. Xu, Z. Zhang, M. Song, T. Lee, M. A. Garcia, B. Xiong, S. Hou, H. R. Tseng, X. Fang, Adv. Mater. 2013, 25, 2368. [131] J. Sharma, R. Chhabra, A. Cheng, J. Brownell, Y. Liu, H. Yan, Science 2009, 323, 112. [132] Y. He, T. Ye, M. Su, C. Zhang, A. E. Ribbe, W. Jiang, C. Mao, Nature 2008, 452, 198. [133] S. M. Douglas, H. Dietz, T. Liedl, B. Högberg, F. Graf, W. M. Shih, Nature 2009, 459, 414. [134] H. Dietz, S. M. Douglas, W. M. Shih, Science 2009, 325, 725. [135] M. Lin, P. Song, G. Zhou, X. Zuo, A. Aldalbahi, X. Lou, J. Shi, C. Fan, Nat. Protoc. 2016, 11, 1244. [136] R. Schlapak, J. Danzberger, D. Armitage, D. Morgan, A. Ebner,\nP. Hinterdorfer, P. Pollheimer, H. J. Gruber, F. Schaffler, S. Howorka, Small 2012, 8, 89. [137] H. Liu, S. Xu, Z. He, A. Deng, J. J. Zhu, Anal. Chem. 2013, 85, 3385. [138] O. N. Assad, T. Gilboa, J. Spitzberg, M. Juhasz, E. Weinhold,\nA. Meller, Adv. Mater. 2017, 29, 1605442. [139] I. Ivanov, J. Stojcic, A. Stanimirovic, E. Sargent, R. K. Nam,\nS. O. Kelley, Anal. Chem. 2013, 85, 398. [140] X. Doldan, P. Fagundez, A. Cayota, J. Laiz, J. P. Tosar, Anal. Chem.\n2016, 88, 10466. [141] D. Cai, L. Ren, H. Zhao, C. Xu, L. Zhang, Y. Yu, H. Wang, Y. Lan,\nM. F. Roberts, J. H. Chuang, M. J. Naughton, Z. Ren, T. C. Chiles, Nat. Nanotechnol. 2010, 5, 597. [142] S. Jeong, J. Park, D. Pathania, C. M. Castro, R. Weissleder, H. Lee, ACS Nano 2016, 10, 1802. [143] J. Homola, Chem. Rev. 2008, 108, 462. [144] S. Mariani, M. Minunni, Anal. Bioanal. Chem. 2014, 406, 2303. [145] L. Zhu, K. Wang, J. Cui, H. Liu, X. Bu, H. Ma, W. Wang, H. Gong,\nC. Lausted, L. Hood, G. Yang, Z. Hu, Anal. Chem. 2014, 86, 8857. [146] H. Im, H. Shao, Y. I. Park, V. M. Peterson, C. M. Castro,\nR. Weissleder, H. Lee, Nat. Biotechnol. 2014, 32, 490. [147] A. G. Brolo, Nat. Photonics 2012, 6, 709. [148] H. Im, N. J. Wittenberg, A. Lesuffleur, N. C. Lindquist, S.-H. Oh,\nChem. Sci. 2010, 1, 688. [149] K. S. Yang, H. Im, S. Hong, I. Pergolini, A. F. del Castillo, R. Wang,\nS. Clardy, C.-H. Huang, C. Pille, S. Ferrone, R. Yang, C. M. Castro, H. Lee, C. F. del Castillo, R. Weissleder, Sci. Transl. Med. 2017, 9, eaal3226.\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (24 of 25)\n[150] J. Hu, Y. Sheng, K. J. Kwak, J. Shi, B. Yu, L. J. Lee, Nat. Commun. 2017, 8, 1683. [151] S. Nie, S. R. Emory, Science 1997, 275, 1102. [152] K. Kneipp, H. Kneipp, J. Kneipp, Acc. Chem. Res. 2006, 39, 443. [153] W. Huang, W. Qian, P. K. Jain, M. A. El-Sayed, Nano Lett. 2007, 7, 3227. [154] S. Mahajan, J. Richardson, T. Brown, P. N. Bartlett, J. Am. Chem. Soc. 2008, 130, 15589. [155] X. Zhang, J. Zhao, A. V. Whitney, J. W. Elam, R. P. Van Duyne, J. Am. Chem. Soc. 2006, 128, 10304. [156] A. J. Chung, Y. S. Huh, D. Erickson, Nanoscale 2011, 3, 2903. [157] X. Wu, Y. Xia, Y. Huang, J. Li, H. Ruan, T. Chen, L. Luo, Z. Shen, A. Wu, ACS Appl. Mater. Interfaces 2016, 8, 19928. [158] D. Y. Zhang, A. J. Turberfield, B. Yurke, E. Winfree, Science 2007, 318, 1121. [159] P. Yin, H. M. T. Choi, C. R. Calvert, N. A. Pierce, Nature 2008, 451, 318. [160] S. A. Melo, L. B. Luecke, C. Kahlert, A. F. Fernandez, S. T. Gammon,\nJ. Kaye, V. S. LeBleu, E. A. Mittendorf, J. Weitz, N. Rahbari, C. Reissfelder, C. Pilarsky, M. F. Fraga, D. Piwnica-Worms, R. Kalluri, Nature 2015, 523, 177. [161] L. Gao, J. Zhuang, L. Nie, J. Zhang, Y. Zhang, N. Gu, T. Wang, J. Feng, D. Yang, S. Perrett, X. Yan, Nat. Nanotechnol. 2007, 2, 577. [162] Z. Zhang, X. Zhang, B. Liu, J. Liu, J. Am. Chem. Soc. 2017, 139, 5412. [163] Z. Chen, S. Luo, C. Liu, Q. Cai, Anal. Bioanal. Chem. 2009, 395, 489. [164] C. D. Medley, J. E. Smith, Z. Tang, Y. Wu, S. Bamrungsap, W. Tan, Anal. Chem. 2008, 80, 1067. [165] H. J. Lee, H. Y. Cho, J. H. Oh, K. Namkoong, J. G. Lee, J. M. Park, S. S. Lee, N. Huh, J. W. Choi, Biosens. Bioelectron. 2013, 47, 508. [166] P. Zuo, X. Li, D. C. Dominguez, B. C. Ye, Lab Chip 2013, 13, 3921. [167] B. Liu, J. Liu, Chem. Commun. 2014, 50, 8568. [168] Y. M. Wang, J. W. Liu, G. B. Adkins, W. Shen, M. P. Trinh, L. Y. Duan, J. H. Jiang, W. Zhong, Anal. Chem. 2017, 89, 12327. [169] S. D. Ibsen, J. Wright, J. M. Lewis, S. Kim, S. Y. Ko, J. Ong,\nS. Manouchehri, A. Vyas, J. Akers, C. C. Chen, B. S. Carter, S. C. Esener, M. J. Heller, ACS Nano 2017, 11, 6641. [170] G. Chen, H. Qiu, P. N. Prasad, X. Chen, Chem. Rev. 2014, 114, 5161. [171] S. Han, R. Deng, X. Xie, X. Liu, Angew. Chem., Int. Ed. 2014, 53, 11702. [172] C. Wang, M. Ye, L. Cheng, R. Li, W. Zhu, Z. Shi, C. Fan, J. He, J. Liu, Z. Liu, Biomaterials 2015, 54, 55. [173] X. Hu, C. W. Wei, J. Xia, I. Pelivanov, M. O’Donnell, X. Gao, Small 2013, 9, 2046. [174] S. Hou, H. Zhao, L. Zhao, Q. Shen, K. S. Wei, D. Y. Suh, A. Nakao, M. A. Garcia, M. Song, T. Lee, B. Xiong, S. C. Luo, H. R. Tseng, H. H. Yu, Adv. Mater. 2013, 25, 1547. [175] J. Chung, M. Yokoyama, M. Yamato, T. Aoyagi, Y. Sakurai, T. Okano, J. Controlled Release 1999, 62, 115. [176] L. Wang, H. Liu, F. Zhang, G. Li, S. Wang, Small 2016, 12, 4697. [177] J. Bu, Y. T. Kang, Y. J. Kim, Y. H. Cho, H. J. Chang, H. Kim, B. I. Moon, H. G. Kim, Lab Chip 2016, 16, 4759. [178] T.-M. Don, M.-L. Huang, A.-C. Chiu, K.-H. Kuo, W.-Y. Chiu, L.-H. Chiu, Mater. Chem. Phys. 2008, 107, 266. [179] L. Chen, M. Liu, L. Lin, T. Zhang, J. Ma, Y. Song, L. Jiang, Soft Matter 2010, 6, 2708. [180] T. Sun, G. Qing, Adv. Mater. 2011, 23, H57. [181] G. Pan, Q. Guo, Y. Ma, H. Yang, B. Li, Angew. Chem., Int. Ed. 2013, 52, 6907. [182] Y. T. Kang, Y. J. Kim, J. Bu, Y. H. Cho, S. W. Han, B. I. Moon, Nanoscale 2017, 9, 13495. [183] M. Li, E. Zeringer, T. Barta, J. Schageman, A. Cheng, A. V. Vlassov,\nPhilos. Trans. R. Soc., B 2014, 369, 20130502.\n[184] K. Shimizu, T. Yukawa, Y. Hirami, R. Okita, S. Saisho, A. Maeda, K. Yasuda, M. Nakata, Targeted Oncol. 2013, 8, 237. [185] K.-M. Rau, H.-K. Chen, L.-Y. Shiu, T.-L. Chao, Y.-P. Lo, C.-C. Wang, M.-C. Lin, C.-C. Huang, Int. J. Mol. Sci. 2016, 17, 524. [186] A. Sottoriva, I. Spiteri, S. G. Piccirillo, A. Touloumis, V. P. Collins, J. C. Marioni, C. Curtis, C. Watts, S. Tavaré, Proc. Natl. Acad. Sci. USA 2013, 110, 4009. [187] S. Sasada, H. Kurihara, T. Kinoshita, M. Yoshida, N. Honda, T. Shimoi, A. Shimomura, K. Yonemori, C. Shimizu, A. Hamada, Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 2146. [188] T. Thorsen, R. W. Roberts, F. H. Arnold, S. R. Quake, Phys. Rev. Lett. 2001, 86, 4163. [189] E. Z. Macosko, A. Basu, R. Satija, J. Nemesh, K. Shekhar, M. Goldman, I. Tirosh, A. R. Bialas, N. Kamitaki, E. M. Martersteck, Cell 2015, 161, 1202. [190] L. Zhao, Y. T. Lu, F. Li, K. Wu, S. Hou, J. Yu, Q. Shen, D. Wu, M. Song, W. H. OuYang, Z. Luo, T. Lee, X. Fang, C. Shao, X. Xu, M. A. Garcia, L. W. Chung, M. Rettig, H. R. Tseng, E. M. Posadas, Adv. Mater. 2013, 25, 2897. [191] Y. Fu, C. Li, S. Lu, W. Zhou, F. Tang, X. S. Xie, Y. Huang, Proc. Natl. Acad. Sci. USA 2015, 112, 11923. [192] E. Sinkala, E. Sollier-Christen, C. Renier, E. Rosas-Canyelles, J. Che, K. Heirich, T. A. Duncombe, J. Vlassakis, K. A. Yamauchi, H. Huang, S. S. Jeffrey, A. E. Herr, Nat. Commun. 2017, 8, 14622. [193] S. P. Gygi, Y. Rochon, B. R. Franza, R. Aebersold, Mol. Cell. Biol. 1999, 19, 1720. [194] B. Zhang, J. Wang, X. Wang, J. Zhu, Q. Liu, Z. Shi, M. C. Chambers, L. J. Zimmerman, K. F. Shaddox, S. Kim, Nature 2014, 513, 382. [195] K. Lee, K. Fraser, B. Ghaddar, K. Yang, E. Kim, L. Balaj, E. A. Chiocca, X. O. Breakefield, H. Lee, R. Weissleder, ACS Nano 2018, 12, 494. [196] W. Shen, K. Guo, G. B. Adkins, Q. Jiang, Y. Liu, S. Sedano, Y. Duan, W. Yan, S. E. Wang, K. Bergersen, D. Worth, E. H. Wilson, W. Zhong, Angew. Chem., Int. Ed. Engl. 2018, https://doi. org/10.1002/anie.201806901. [197] S. Yadav, K. Boriachek, M. N. Islam, R. Lobb, A. Möller, M. M. Hill, M. S. A. Hossain, N.-T. Nguyen, M. J. A. Shiddiky, ChemElectroChem 2017, 4, 967. [198] E. Salvati, F. Stellacci, S. Krol, Nanomedicine 2015, 10, 3495. [199] A. Liga, A. D. Vliegenthart, W. Oosthuyzen, J. W. Dear,\nM. Kersaudy-Kerhoas, Lab Chip 2015, 15, 2388. [200] Z. Liu, W. Zhang, F. Huang, H. Feng, W. Shu, X. Xu, Y. Chen, Biosens. Bioelectron. 2013, 47, 113. [201] C. Chen, J. Skog, C. H. Hsu, R. T. Lessard, L. Balaj, T. Wurdinger,\nB. S. Carter, X. O. Breakefield, M. Toner, D. Irimia, Lab Chip 2010, 10, 505.\n[202] E. K. Sackmann, A. L. Fulton, D. J. Beebe, Nature 2014, 507, 181. [203] K. Boriachek, M. N. Islam, A. Moller, C. Salomon, N. T. Nguyen,\nM. S. A. Hossain, Y. Yamauchi, M. J. A. Shiddiky, Small 2018, 14, 1702153. [204] H. Shao, H. Im, C. M. Castro, X. Breakefield, R. Weissleder, H. Lee, Chem. Rev. 2018, 118, 1917. [205] R. M. Mohamadi, J. D. Besant, A. Mepham, B. Green, L. Mahmoudian, T. Gibbs, I. Ivanov, A. Malvea, J. Stojcic, A. L. Allan, L. E. Lowes, E. H. Sargent, R. K. Nam, S. O. Kelley, Angew. Chem., Int. Ed. 2015, 54, 139. [206] S. Kim, S. I. Han, M. J. Park, C. W. Jeon, Y. D. Joo, I. H. Choi, K. H. Han, Anal. Chem. 2013, 85, 2779. [207] S. A. Hosseini, M. Abdolahad, S. Zanganeh, M. Dahmardeh, M. Gharooni, H. Abiri, A. Alikhani, S. Mohajerzadeh, O. Mashinchian, Small 2016, 12, 883. [208] T. S. Safaei, R. M. Mohamadi, E. H. Sargent, S. O. Kelley, ACS Appl. Mater. Interfaces 2015, 7, 14165. [209] Z. Wang, H. J. Wu, D. Fine, J. Schmulen, Y. Hu, B. Godin, J. X. Zhang, X. Liu, Lab Chip 2013, 13, 2879.\nAdv. Mater. 2018, 1805344\n© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805344 (25 of 25)\n[210] S. L. Stott, C. H. Hsu, D. I. Tsukrov, M. Yu, D. T. Miyamoto, B. A. Waltman, S. M. Rothenberg, A. M. Shah, M. E. Smas, G. K. Korir, F. P. Floyd Jr., A. J. Gilman, J. B. Lord, D. Winokur, S. Springer, D. Irimia, S. Nagrath, L. V. Sequist, R. J. Lee, K. J. Isselbacher, S. Maheswaran, D. A. Haber, M. Toner, Proc. Natl. Acad. Sci. USA 2010, 107, 18392. [211] M. G. Ahmed, M. F. Abate, Y. Song, Z. Zhu, F. Yan, Y. Xu, X. Wang, Q. Li, C. Yang, Angew. Chem., Int. Ed. 2017, 56, 10681. [212] A. F. Sarioglu, N. Aceto, N. Kojic, M. C. Donaldson, M. Zeinali, B. Hamza, A. Engstrom, H. Zhu, T. K. Sundaresan, D. T. Miyamoto, X. Luo, A. Bardia, B. S. Wittner, S. Ramaswamy, T. Shioda, D. T. Ting, S. L. Stott, R. Kapur, S. Maheswaran, D. A. Haber, M. Toner, Nat. Methods 2015, 12, 685. [213] P. Li, Z. M. Mao, Z. L. Peng, L. L. Zhou, Y. C. Chen, P. H. Huang, C. I. Truica, J. J. Drabick, W. S. El-Deiry, M. Dao, S. Suresh, T. J. Huang, Proc. Natl. Acad. Sci. USA 2015, 112, 4970. [214] B. H. Wunsch, J. T. Smith, S. M. Gifford, C. Wang, M. Brink, R. L. Bruce, R. H. Austin, G. Stolovitzky, Y. Astier, Nat. Nanotechnol. 2016, 11, 936. [215] Y. Yoshioka, Y. Konishi, N. Kosaka, T. Katsuda, T. Kato, T. Ochiya, J. Extracell. Vesicles 2013, 2, 20424. [216] E. Reategui, K. E. van der Vos, C. P. Lai, M. Zeinali, N. A. Atai, B. Aldikacti, F. P. Floyd Jr., H. K. A, V. Thapar, F. H. Hochberg, L. V. Sequist, B. V. Nahed, B. S Carter, M. Toner, L. Balaj, T. T. D, X. O. Breakefield, S. L. Stott, Nat. Commun. 2018, 9, 175. [217] E. Ozkumur, A. M. Shah, J. C. Ciciliano, B. L. Emmink, D. T. Miyamoto, E. Brachtel, M. Yu, P.-i. Chen, B. Morgan, J. Trautwein, A. Kimura, S. Sengupta, S. L. Stott, N. M. Karabacak, T. A. Barber, J. R. Walsh, K. Smith, P. S. Spuhler, J. P. Sullivan, R. J. Lee, D. T. Ting, X. Luo, A. T. Shaw, A. Bardia, L. V. Sequist, D. N. Louis, S. Maheswaran, R. Kapur, D. A. Haber, M. Toner, Sci. Transl. Med. 2013, 5, 179ra47. [218] C. Liu, J. Guo, F. Tian, N. Yang, F. Yan, Y. Ding, J. Wei, G. Hu, G. Nie, J. Sun, ACS Nano 2017, 11, 6968. [219] C. Liu, C. Xue, X. Chen, L. Shan, Y. Tian, G. Hu, Anal. Chem. 2015, 87, 6041. [220] D. Yuan, J. Zhang, R. Sluyter, Q. Zhao, S. Yan, G. Alici, W. Li, Lab Chip 2016, 16, 3919. [221] V. P. Gavrilenko, E. N. Lesnovsky, Y. A. Novikov, A. V. Rakov, P. A. Todua, M. N. Filippov, Bull. Russ. Acad. Sci.: Phys. 2009, 73, 433. [222] M. Baker, Nature 2016, 533, 452. [223] Y. Zhang, J. Yang, H. Li, Y. Wu, H. Zhang, W. Chen, Int. J. Clin. Exp. Med. 2015, 8, 11683.\nAdv. Mater. 2018, 1805344"
    } ],
    "references" : [ {
      "title" : "H",
      "author" : [ "W. Li", "B. Shao", "C. Liu", "H. Wang", "W. Zheng", "W. Kong", "X. Liu", "G. Xu", "C. Wang" ],
      "venue" : "Li, Small Methods 2",
      "citeRegEx" : "72",
      "shortCiteRegEx" : null,
      "year" : 2018
    }, {
      "title" : "Proteomic Profiling (Ed: A",
      "author" : [ "D.W. Greening", "R. Xu", "H. Ji", "B.J. Tauro", "R.J. Simpson" ],
      "venue" : null,
      "citeRegEx" : "117",
      "shortCiteRegEx" : "117",
      "year" : 2015
    }, {
      "title" : "M",
      "author" : [ "X. Hu", "C.W. Wei", "J. Xia", "I. Pelivanov" ],
      "venue" : "O’Donnell, X. Gao, Small 2013, 9",
      "citeRegEx" : "173",
      "shortCiteRegEx" : null,
      "year" : 2046
    }, {
      "title" : "Chem",
      "author" : [ "H. Shao", "H. Im", "C.M. Castro", "X. Breakefield", "R. Weissleder", "H. Lee" ],
      "venue" : "Rev. 2018, 118",
      "citeRegEx" : "204",
      "shortCiteRegEx" : null,
      "year" : 1917
    } ],
    "referenceMentions" : [ {
      "referenceID" : 1,
      "context" : "The ExoTIC system exhibited comparable capture efficiency to the one with ultracentrifugation that was the most commonly used method for EV isolation.[116,117] It is well known that the nanoscaled cellular surface components (e.",
      "startOffset" : 150,
      "endOffset" : 159
    }, {
      "referenceID" : 2,
      "context" : "reported a novel photoacoustic imaging technology for the detecting of CTCs at single cell mL−1 level based on the magneto-optical coupled nanoprobes.[173] The multifunctional nanoprobes were composed of a gold nanorod core, a thin silica shell, multiple iron oxide-based MNPs, and an outer layer of polyethylene glycol (PEG) with a terminal targeting folic acid (Figure 7d).",
      "startOffset" : 150,
      "endOffset" : 155
    }, {
      "referenceID" : 2,
      "context" : "Reproduced with permission.[173] Copyright 2013, Wiley-VCH",
      "startOffset" : 27,
      "endOffset" : 32
    } ],
    "year" : 2018,
    "abstractText" : "W. Li, H. Wang, Dr. Z. Zhao, H. Gao, C. Liu, Dr. L. Zhu, Prof. C. Wang, Prof. Y. Yang CAS Key Laboratory of Standardization and Measurement for Nanotechnology CAS Key Laboratory of Biological Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology Beijing 100190, China E-mail: zhul@nanoctr.cn; wangch@nanoctr.cn; yangyl@nanoctr.cn The ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adma.201805344.",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}